CXCR4-Targeted Nanotherapeutics: A Promising Approach for Liver Fibrosis and Hepatocellular Carcinoma Management

Introduction

Chronic liver diseases (CLDs) represents a significant global public health problem, affecting nearly 844 million individuals and resulting in approximately 2 million deaths annually.¹ Liver fibrosis (LF) serves as a progressive stage in CLDs and arises from diverse etiologies such as chronic viral diseases (eg., hepatitis B and C viruses), metabolic dysregulation, excessive alcohol consumption, autoimmune diseases, and cholestatic injury etc.^1,2 Non-alcoholic fatty liver disease (NAFLD) affects approximately 25% of the global population, with a subset progressing to non-alcoholic steatohepatitis (NASH) and LF.^3–6 LF is typically asymptomatic and often remains undetected until advanced stages because of the absence of explicit clinical indicators during its early stages of development. LF is characterized by the excessive accumulation of extracellular matrix (ECM), which destroys the physiological architecture of the liver, resulting from chronic liver injury.^7–10 Persistent tissue damage and excessive ECM deposition results in progressive hepatic stiffening and functional decline. Over time, this fibrotic progression can progress to cirrhosis and hepatocellular carcinoma (HCC), often accompanied by severe problems including portal hypertension, hepatic encephalopathy, and eventually liver failure.^11,12 HCC accounts for over 80% of primary liver tumor cases globally and imposes a substantial disease burden, ranking among the foremost causes of cancer-related mortalities.¹³ Halder T, in 2024 reported that HCC is the fourth leading cause of cancer-related deaths globally and is a critical public health challenge, particularly in regions with a high prevalence. As the sixth most common cancer worldwide, HCC’s exceptionally high mortality rate positions it as the third leading cause of cancer-related deaths, accounting for approximately 700,000 fatalities annually.¹⁴ Geographically, the highest incidence rates are observed in Africa, Asia, such as Thailand, Vietnam, and Cambodia with the highest age-standardized rate of 93.7 per 100,000 individuals.² However, China has the highest absolute number of cases owing to its substantial population (1.4 billion) and an elevated incidence rate of 18.3 per 100,000. These epidemiological patterns underscore the disproportionate impact of HCC in specific regions, necessitating targeted interventions to address this major oncological challenge.^15–17

Pathophysiology of Liver Fibrosis

Several factors, including autoimmune disorders, alcohol consumption, viral infections, certain medications, and metabolic conditions, contribute to liver damage by activating HSCs. Upon activation, HSCs undergo processes such as proliferation, loss of retinoids, increased contractility, and fibrosis, all of which contribute to the formation of liver scars. The release of chemokines and cytokines from liver cells and macrophages further exacerbates fibrosis progression, leading to increased liver stiffness and impaired function. While activated HSCs may revert to a quiescent state or remain persistently activated, inflammatory signals from immune cells, particularly macrophages, continue to promote fibrosis. Chemotaxis guides activated HSCs to the injury site in response to signals like CXCL12. Retinoid depletion in HSCs accelerates their activation and proliferation, thereby facilitating fibrosis. Activated HSCs also exhibit contractility, contributing to tissue stiffness, while excessive deposition of collagen and other ECM components fosters fibrogenesis. Although ECM degradation is part of the tissue remodeling process, excessive ECM accumulation results in fibrosis. If left unresolved, fibrosis may progress to cirrhosis, heightening the risk of severe complications such as portal hypertension, hepatic encephalopathy (HE), HCC and liver failure. However, the reversion of HSCs activation and induction of apoptosis may help mitigate fibrosis progression (Figure 1).¹

Figure 1 Fundamental role of HSCs in liver fibrogenesis and regression. Chronic liver injury triggers hepatocyte and biliary epithelial cell damage, leading to the release of pro-fibrogenic mediators from Kupffer cells and macrophages. These signals activate quiescent HSCs (qHSCs), transitioning them into activated HSCs. Upon activation, HSCs undergo phenotypic changes, involving retinoid loss, increased proliferation, contractility, ECM deposition, chemotaxis impaired matrix degradation, and pro-inflammatory signaling. Sustained HSCs activation drives progressive LF, which may advance to cirrhosis, hepatocellular carcinoma, and associated complications such as portal hypertension and hepatic encephalopathy Gu L, Zhang F, Wu J, Zhuge Y. Nanotechnology in Drug Delivery for LF. Front Mol Biosci. 2022 Jan 11;8:804396. doi: 10.3389/fmolb.2021.804396. PMID: 35087870; PMCID: PMC8787125. Copyright © 2022 Gu, Zhang, Wu and Zhuge.1

Harnessing CXCR4 Antagonism for Targeted Therapy in Liver Fibrosis

CXCR4 is a membrane protein and G protein-coupled receptor (GPCR) that plays a critical role in regulating cell migration and trafficking, especially of immune cells. It is widely expressed across various tissues and organs, participating in numerous physiological functions and pathological processes. CXCR4 binds to its natural ligand, SDF-1 (CXCL12), triggering structural changes that activate the receptor. The activation of CXCR4 leads to the engagement of the Gαi subunit of the G protein complex, which in turn activates several downstream signaling pathways, including PI3K (Phosphoinositide 3-kinase), PLC (Phospholipase C), JAK/STAT (Janus Kinase/Signal Transducers and Activators of Transcription), and MAPK (Mitogen-Activated Protein Kinase). These pathways regulate processes such as calcium mobilization, cell migration, immune responses, and stem cell homing, which are essential for immune cell trafficking to infection and inflammation sites.¹⁸ The CXCL12/CXCR4 axis plays a central role in the pathophysiology of LF, a progressive condition characterized by ECM deposition in response to sustained liver injury. Under normal conditions, HSCs are in a quiescent state; however, following liver damage, the secretion of CXCL12 triggers their activation, leading to their trans differentiation into fibrogenic myofibroblasts. The CXCR4 receptor, which is expressed on the surface of these cells, mediates the cellular response to CXCL12, positioning it as a crucial mediator in the fibrotic cascade.¹⁹ In recent years, therapeutic strategies have aimed at targeting this signaling pathway to prevent or reverse fibrosis progression. One such approach involves the use of nanoparticles (NPs) specifically designed to target CXCR4. These NPs, when administered intravenously, selectively bind to CXCR4, thereby inhibiting the CXCL12/CXCR4 axis and preventing the activation of HSCs. By disrupting this pathway, the NPs help mitigate excessive ECM accumulation and restrain the progression of LF. This targeted therapy offers a more refined and potentially more effective approach to treating LF, with the advantage of minimizing the side effects often associated with conventional antifibrotic treatments. Ultimately, targeting the CXCL12/CXCR4 axis represents a promising and highly specific therapeutic strategy, with the potential to halt or even reverse LF, while also preventing its progression to cirrhosis and HCC.²⁰ Targeting CXCR4 with precise drug delivery systems offers a promising approach to halt or reverse fibrosis progression (Figure 2). In conclusion, functionalized NPs targeting CXCR4 offer a promising approach for enhancing precision therapy and diagnostics, with improved specificity and efficacy in liver cell treatment. These advances hold significant potential for more targeted and effective clinical interventions.

Figure 2 A schematic illustration of the mechanism of CXCR4-targeted therapy of LF. In a normal liver, quiescent HSCs remain inactive. During LF, the activation of HSCs is driven by CXCL12 and its binding to CXCR4. CXCR4-targeted NPs, administered via intravenous injection, specifically bind to CXCR4 on activated HSCs, blocking the CXCL12/CXCR4 axis, which inhibits fibrosis progression by preventing the activation of HSCs and ECM accumulation.

Pathological Role of CXCR4 in Liver Diseases

The CXCR4/CXCL12 axis plays a critical role in the pathogenesis of liver diseases, particularly in LF and HCC.^21–23 This signaling pathway is involved in a range of processes such as HSCs activation, immune cell recruitment, ECM deposition, and tumor progression, making it a promising therapeutic target for liver-related diseases.^24–27

CXCR4/CXCL12 Signaling in Liver Fibrosis

LF arises from a persistent wound healing response triggered by chronic liver injury, which serves as a compensatory mechanism to maintain hepatic integrity.²⁸ Without intervention, progressive fibrosis can lead to cirrhosis, and HCC.^29,30 HSCs are recognized as the primary drivers of fibrogenesis, orchestrating excessive ECM deposition via activation and proliferation.³¹ Recent studies underscore the pivotal role of the CXCR4/CXCL12 axis in this process, with both ligand and receptor markedly upregulated in fibrotic and cirrhotic livers.^32,33 Upon binding CXCL12, CXCR4-expressing HSCs undergo activation and migration through the MAPK, ERK1/2, and PI3K/Akt signaling pathways, amplifying fibrotic outcomes.^34,35 This engagement also induces calcium-independent HSCs contraction and collagen I production, perpetuating fibrosis.^36,37 In co-infections such as HIV/HCV, the HIV-1 gp120 protein interacts with CXCR4 on HSCs, activating ERK1/2 phosphorylation and ROS generation, which further stimulates profibrogenic gene expression.^38,39 Additionally, CXCR4 plays a role in modulating liver sinusoidal endothelial cells (LSECs), which sustain HSCs proliferation.⁴⁰ The CXCL12/CXCR4 axis is also involved in the recruitment of bone marrow-derived mesenchymal stem cells (MSCs) to the site of injury. Interestingly, the role of MSCs is paradoxical, as they can either exacerbate ECM deposition or promote tissue remodeling depending on the context.^41,42 Inhibition of CXCR4 in MSCs attenuates their recruitment to fibrotic lesions, highlighting the therapeutic potential of targeting this axis.⁴³

NP-based therapies targeting CXCR4 have shown promising results in reducing fibrosis. For example, CXCR4-targeted NPs delivered TGF β siRNA effectively and normalized fibrotic vasculature and inhibited HSCs proliferation.⁴¹ Additionally, CXCR4-targeted combination therapies blocked CXCL12/CXCR4 pathway and reduced the fibrotic biomarkers, leading to significant fibrosis regression and HCC.^44,45 Given the importance of CXCR4 in HSCs activation and fibrotic progression, the targeted disruption of CXCR4 and its ligand interactions may be a promising therapeutic strategy for mitigating LF.

CXCR4/CXCL12 Signaling in HCC

The CXCL12/CXCR4 signaling plays a crucial role in HCC progression by promoting tumor growth, immune evasion, and metastasis.²¹ Elevated CXCL12 and CXCR4 expression levels in HCC correlate with aggressive tumor behavior, lymph node metastasis, and poor prognosis.^46–48 Within the TME, CXCL12 recruits immunosuppressive CD4+CD25+ Treg cells, which support tumor progression by fostering an immune-tolerant niche.⁴⁹

Activation of the CXCL12/CXCR4 axis enhances tumor cell migration, angiogenesis, and metastasis via the MAPK/ERK and PI3K/Akt signaling pathways.⁵⁰ Also, CXCR4 activation in endothelial cells facilitates HCC-associated angiogenesis through ERK signaling, promoting the formation of sinusoidal vasculature characterized by upregulation of molecules such as VE-cadherin, MMP2, and laminin5γ2, which enable blood perfusion to the tumor.^50–52 The CXCL12/CXCR4 axis influences tumor cell metastasis by promoting matrix remodeling through the upregulation of MMP10 via ERK1/2, which accelerates HCC metastasis.⁵³ Furthermore, CXCR4 activation induces the recruitment of Annexin A2 and Rac to the actin cytoskeleton, enhancing chemotaxis and facilitating the metastatic spread of HCC cells.⁵⁴ Recent studies have identified CXCR4 as a mechano-transducer, where Ubiquitin Domain Containing 1 (UBTD1) links ECM to YAP signaling pathway, further promoting tumor aggressiveness.⁵⁵

Clinically, overexpression of CXCR4 correlates with poor prognosis in HCC. Its inhibition through genetic knockdown, small molecules like AMD3100, or neutralizing antibodies significantly suppresses tumor progression, cell invasion, and metastasis.^54,56 Targeting CXCR4 also reverses epithelial-to-mesenchymal transition (EMT), enhancing chemosensitivity and inhibiting HCC cell proliferation.⁵⁷

Natural compounds, such as emodin and plumbagin, have been shown to modulate CXCR4 activity, thereby reducing invasion and angiogenesis in HCC cells.^57,58 Resistance to conventional therapies, such as sorafenib, in advanced HCC is frequently associated with the upregulation of the CXCL12/CXCR4 signaling pathway. To address this challenge, innovative strategies that utilize CXCR4-targeted NPs for the delivery of sorafenib, in combination with MEK inhibitors, have demonstrated improved anti-tumor efficacy.^59,60 These findings highlight the promising therapeutic potential of targeting the CXCL12/CXCR4 axis in the treatment of HCC.

Pathophysiological Role of CXCR4 in Angiogenesis and Inflammation

CXCR4 plays a pivotal role in both LF and HCC, primarily through its involvement in inflammation and angiogenesis. In the context of LF, B cells significantly contribute to disease progression. Zhang et al hypothesized that disruption of cholangiocyte-B cell interactions via inhibition of the CXCL12/CXCR4 axis could attenuate LF. Furthermore, celecoxib inhibited cholangiocyte proliferation and CXCL12 expression, and CXCL12-deficient mice exhibited attenuated LF and reduced B-cell infiltration. Single-cell RNA sequencing and flow cytometry identified CXCR4 as a marker for profibrotic liver-homing B cells, with celecoxib diminishing their infiltration and thus attenuating LF. Collectively, these findings demonstrate CXCL12-CXCR4 axis through celecoxib’s COX-2-independent effects disrupts cholangiocyte-B cell interactions, offering a potential therapeutic strategy for LF (Figure 3).⁶¹

Figure 3 A schematic illustration of the disruption of the CXCL12/CXCR4 signaling axis in cholangiocyte-B cell interactions and its impact on LF. In mild LF, CXCR4 on B cells mediates the secretion of profibrotic cytokines, promoting HSCs activation and collagen fiber deposition. In severe LF, this signaling pathway is further exacerbated. Celecoxib, a COX-2 inhibitor, is shown to reduce cholangiocyte hyperplasia, but the reduction in LF occurs via a mechanism independent of COX-2 inhibition, through the disruption of CXCL12/CXCR4 signaling axis, which inhibits fibrosis progression.

Figure 4 Mechanism of SOX4 upregulation in HCC cells. The upregulation of SOX4 in HCC cells triggers the transcription of CXCL12, which is subsequently expressed on the cell surface. This increase in CXCL12 enhances the expression of CXCR4 on endothelial cells. The elevated CXCR4 expression promotes endothelial cell chemotaxis and stimulates angiogenesis, which in turn facilitates tumor growth and metastasis in HCC. Each step in this mechanistic pathway marks an increase in gene expression or cellular activity, contributing to the progression of cancer.

In addition to its role in inflammation, CXCR4 is also critical in angiogenesis, particularly in the progression of HCC. SOX4 activates the CXCL12-CXCR4 axis by upregulating CXCL12 expression, which in turn drives endothelial cell chemotaxis and tube formation, crucial steps in angiogenesis in HCC clinical samples (Figure 4). Luciferase reporter and chromatin immunoprecipitation assays demonstrated that SOX4 directly activates the CXCL12 whereas SOX4 knockdown inhibits this transcriptional activity. CRISPR/Cas9-mediated SOX4 knockout in Hep3B cells downregulated CXCL12 expression, leading to impaired chemotaxis and tube formation in Human Umbilical Vein Endothelial Cells (HUVECs). Moreover, SOX4 depletion in vivo suppressed tumor growth, angiogenesis, and reticular fiber deposition.⁶² Pharmacological inhibition of CXCR4 with AMD3100 disrupted endothelial cell chemotaxis and tube formation, underscoring the role of the CXCL12/CXCR4 signaling pathway in HCC angiogenesis, highlighting targeting the SOX4-CXCL12-CXCR4 axis as a therapeutic strategy for HCC by inhibiting angiogenesis and metastasis, ultimately limiting tumor growth and spread (Figure 4).⁶² Conclusively, the SOX4-CXCL12-CXCR4 signaling axis plays a crucial role in HCC progression by promoting angiogenesis, modulating the TME, and facilitating metastasis, making it a promising therapeutic target for limiting tumor growth and spread.

CXCR4 and Therapeutic Strategies

Small molecules CXCR4 antagonists for disruption of CXCR4 Signaling

Accumulating evidence highlights the CXCL12/CXCR4 axis as a promising target for therapeutic intervention in fibrosis. Recent developments in drug research have led to the discovery of several small-molecule CXCR4 inhibitors, with some advancing to early-phase clinical trials, demonstrating their antifibrotic potential through the inhibition of CXCL12-CXCR4 binding across multiple organ systems.^41,63,64 The CXCR4 signaling pathway plays a critical role in the progression of LF and HCC by promoting HSCs activation, enhancing tumor cell migration, and facilitating angiogenesis. Targeting CXCR4 provides a promising strategy for treating fibrosis by inhibiting HSCs activation, reducing ECM deposition, and attenuating inflammatory signaling within the liver. CXCR4 antagonists hold considerable potential in HCC therapy by modulating the TME. These agents can inhibit tumor cell migration, angiogenesis, and metastasis while simultaneously enhancing immune responses, thereby augmenting the effectiveness of existing therapeutic strategies.^21,65

AMD3100 (plerixafor) is the FDA-approved small-molecule CXCR4 antagonist.⁶⁶ Mechanistically, AMD3100 functions as a competitive antagonist and effectively inhibits CXCL12 binding by directly occupying the CXCR4 receptor.^67,68 AMD3100-mediated CXCR4 blockade exerts potent anti-fibrotic effects by disrupting the CXCL12/CXCR4 axis, which drives HSCs and ECM deposition. In a CCl4-induced metabolic dysfunction-associated steatotic liver disease (MASLD) murine model, AMD3100 specifically reduced collagen accumulation and liver stiffness, highlighting CXCR4 inhibition as a critical component in inhibiting the fibrosis cycle in metabolic liver disease.⁶⁹ Similarly, SOX4 modulates the CXCL12 promoter in HCC cells, whereas CXCR4 in endothelial cells facilitates tumor neovascularization, thereby establishing a chemotaxis-driven angiogenic mechanism. In vitro findings revealed that AMD3100 effectively inhibited tube formation and endothelial cell migration. Additionally, In vivo validation via F-FDG PET/CT imaging showed significantly reduced metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in AMD3100-treated groups compared with controls. Histopathological analysis further confirmed diminished angiogenesis, as evidenced by decreased reticulin and CD34 staining in Hep3B-derived tumors following AMD3100 treatment, although SOX4 expression remained unchanged. Collectively, these results highlight the critical role of the CXCL12/CXCR4 axis in SOX4-mediated angiogenesis, which can be effectively targeted by CXCR4 inhibition using AMD3100.⁷⁰

BPRCX807 is a highly selective and potent CXCR4 antagonist that effectively targets the CXCR4 receptor on endothelial cells and TAMs, key players in tumor progression and metastasis. By blocking the CXCL12/CXCR4 signaling axis, BPRCX807 inhibits critical processes such as endothelial cell migration and angiogenesis, both of which are essential for tumor growth and metastasis. In addition, BPRCX807 prevents the polarization of TAMs towards the immunosuppressive M2 phenotype, instead promoting their reprogramming to the immunostimulatory M1 phenotype, thus enhancing the anti-tumor immune response. This reprogramming of TAMs plays a significant role in counteracting tumor-induced immune evasion. Furthermore, BPRCX807 suppresses downstream signaling pathways, including ERK and AKT, which are implicated in immune cell recruitment and EMT both of which are crucial for tumor invasion and metastasis.

In preclinical in vivo HCC models, BPRCX807 has demonstrated superior antitumor efficacy, effectively inhibiting primary tumor growth, suppressing metastasis, and reprogramming the TME by reducing TAM infiltration. As a monotherapy, BPRCX807 has been shown to prolong survival compared to conventional treatments such as sorafenib or anti-PD-1 therapy. Additionally, its combination with either sorafenib or anti-PD-1 therapy significantly enhances survival and suppresses metastatic progression, highlighting its potential as a powerful therapeutic strategy for HCC. These findings underscore the clinical promise of BPRCX807 as a versatile agent for targeting the CXCR4 axis in cancer therapy. By overcoming key limitations of previous CXCR4 inhibitors, BPRCX807 presents a compelling option for combination therapies with antiangiogenic agents or immunotherapies, further enhancing its potential in cancer treatment (Figure 5).⁷¹

Figure 5 Mechanism of action BPRCX807, a selective CXCR4 antagonist, blocks the CXCL12/CXCR4 axis and its role in suppressing HCC progression. BPRCX807, a potent and metabolically stable selective CXCR4 antagonist, effectively blocks the CXCL12/CXCR4 axis, playing a critical role in inhibiting HCC progression. By suppressing the Akt and ERK signaling pathways, BPRCX807 prevents both primary tumor growth and distal metastasis. Additionally, it modulates the immunosuppressive TME through the polarization of TAMs and inhibition of angiogenesis, further contributing to its therapeutic efficacy in HCC.

CXCR4 Signaling and Polymeric CXCR4 Antagonists

Alcohol-associated liver disease (AALD) is a major cause of hepatic disorders, with few effective treatment options, particularly for LF. Emerging therapeutic strategies focus on RNA interference targeting miR-155 overexpression in Kupffer cells (KCs) and the use of CXCR4 antagonists to inhibit HSCs activation through the CXCL12/CXCR4 signaling pathway. Cholesterol-modified polymeric CXCR4 inhibitors (Chol-PCX) have shown promise in delivering anti-miR-155 or non-coding (NC) miRNAs, forming stable Chol-PCX/miRNA NP complexes. Treatment with Chol-PCX/anti-miR-155 NPs has been shown to significantly reduce hepatic injury, as indicated by lower serum aminotransferase levels and diminished collagen deposition, thus preventing fibrotic progression. The dual functionality of Chol-PCX, which combines CXCR4 receptor antagonism with targeted miRNA delivery, presents a promising therapeutic approach for fibrosis induced by AALD. By selectively inhibiting CXCR4, a key mediator of fibrogenesis, Chol-PCX/anti-miR-155 NPs offer a synergistic strategy to halt disease progression. These results reinforce the critical role of CXCR4 as a therapeutic target and support the potential of NPs-mediated CXCR4 inhibition in the treatment of LF (Figure 6).⁷²

Figure 6 A schematic illustration of the mechanism of CXCR4 inhibition in LF treatment. The figure illustrates the mechanism of CXCR4 inhibition in LF treatment using Cyclam-modified NPs. In a mouse model of LF, these NPs specifically target CXCR4 on aHSCs, delivering miR-155 to suppress profibrotic signaling. This targeted inhibition reduces the expression of α-smooth muscle actin and prevents further activation of HSCs, thereby mitigating the progression of fibrosis. The pathway is shown where CXCR4 signaling is suppressed, leading to a reduction in HSCs activation and fibrosis development.

CXCR4 Signaling and Gene Silencing

Gene silencing downregulates CXCR4 expression in fibrotic livers. Liu et al developed CXCR4-targeted NPs for targeted delivery of VEGF siRNA to fibrotic livers, demonstrating potent anti-angiogenic effects. These NPs incorporated AMD3100 as both a targeting ligand and therapeutic agent, achieving dual functionality: (1) specific CXCR4-mediated tissue homing and (2) direct suppression of HSCs proliferation and activation. In a CCl4-induced murine fibrosis model, the targeted NPs effectively delivered VEGF siRNA to damaged liver tissue, resulting in significant VEGF knockdown, marked angiogenesis inhibition, which are characteristic of fibrotic progression. Importantly, the combinatorial blockade of both CXCR4/SDF-1 signaling (via AMD3100) and VEGF expression (via VEGF siRNA) produced synergistic anti-fibrotic effects, substantially attenuating disease progression. These findings establish CXCR4-targeted NPs as a promising platform for multi-mechanistic anti-fibrotic therapy (Figure 7).³³ CXCR4-targeted NPs effectively deliver VEGF siRNA to fibrotic liver tissue, producing synergistic anti-fibrotic effects by inhibiting angiogenesis and HSCs activation. This approach offers a promising multi-mechanistic strategy for combating LF and HCC.

Figure 7 Targeting VEGF and CXCR4/SDF-1 signaling axis in LF treatment. A schematic illustration of the progression of LF in a normal versus fibrotic liver, with and without treatment. In a healthy liver, HSCs remain quiescent, and blood vessels are normal. In LF, HSCs are activated, leading to increased HSCs proliferation, MVD, and vessel distortion. The treatment approach, using VEGF siRNA-loaded AMD-NPs, blocks the CXCR4/SDF-1 axis, downregulates VEGF expression, and reduces HSCs activation and MVD, ultimately normalizing the liver vasculature. Reprinted with permission from Chun-Hung Liu†Kun-Ming Chan§Tsaiyu Chiang†Jia-Yu Liu†Guann-Gen Chern†Fu-Fei Hsu∥Yu-Hsuan Wu§Ya-Chi Liu†Yunching Chen*†. Dual-Functional NPs Targeting CXCR4 and Delivering Antiangiogenic siRNA Ameliorate LF. Mol. Pharmaceutics 2016, 13, 7, 2253–2262. Copyright © 2016 American Chemical Society.41

Peptide Inhibitors Disrupt CXCR4 Signaling

Through an integrated medium-throughput screening and rational design approach, LY2510924 was found to be a peptide CXCR4 antagonist containing amino acids that potently inhibits the CXCL12/CXCR4 axis and downstream signaling pathways (NCT01391130, NCT1439568). Its ability to sustain CXCR4 receptor occupancy and trigger significant pharmacodynamic responses, including increased ANC and CD34+ cell counts, highlights its therapeutic potential. In conclusion, LY2510924 is a potent peptide CXCR4 antagonist that effectively disrupts the CXCL12/CXCR4 axis and downstream signaling, may meilorate LF and HCC.⁷³

Bioactive Molecules as CXCR4 Antagonists

Albiflorin (ALB), a pinane-type monoterpene derived from Paeonia lactiflora Pall., demonstrates potent anti-inflammatory and hepatoprotective properties, making it a promising candidate for the treatment of LF. Mechanistically, ALB exerts its anti-fibrotic effects by disrupting the CXCL12/CXCR4 signaling axis, a pathway implicated in fibrosis progression. In preclinical models, ALB showed comparable efficacy to AMD3100, a known CXCR4 antagonist, in attenuating CCl4-induced liver injury. Specifically, ALB suppressed TGF-β1-induced activation of LX-2 cells in vitro, resulting in a reduction of α-SMA and collagen I expression, key markers of fibrosis. Additionally, ALB effectively mitigated inflammatory cascades, further curbing fibrogenesis. In vivo, ALB treatment significantly reduced fibrosis markers, improved hepatic function, and restored liver tissue architecture in CCl4-treated mice.

Interestingly, combining ALB with metformin (MET), a well-established metabolic regulator, resulted in a synergistic enhancement of anti-fibrotic effects, highlighting the potential of combination therapy for more effective management of LF. These findings underscore the dual therapeutic potential of ALB and MET combination therapy, via CXCR4 inhibition to target fibrotic signaling axis and metabolic pathways respectively, offering a novel and integrated approach to LF treatment. The results suggest that ALB could be utilized either as a monotherapy or as an adjunct to existing therapies, bridging a critical gap in the management of chronic hepatic injury and its progression to HCC (Figure 8).⁷⁴

Figure 8 A schematic illustrating the antifibrotic effects of ALB and its combination with MET in LF treatment. The figure illustrates the antifibrotic effects of ALB and its combination with MET in the treatment of LF. ALB inhibits the CXCL12-CXCR4 signaling axis, thereby reducing the progression of LF. When combined with MET, ALB further enhances the inhibition of CXCR4 signaling, preventing the downstream activation of key pathways such as p38 MAPK, JAK, and STAT3. This inhibition reduces the expression of critical fibrosis markers, including α-SMA and collagen I, and decreases the levels of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and NLRP3, ultimately mitigating fibrosis. The schematic provides a detailed view of how these treatments impact activated HSCs and modulate fibrotic signaling in the liver. Meng L, Lv H, Liu A, Cao Q, Du X, Li C, Li Q, Luo Q, Xiao Y. Albiflorin inhibits inflammation to improve LF. by targeting the CXCL12/CXCR4 axis in mice. Front Pharmacol. 2025 Apr 30;16:1577201. Copyright © 2025 Meng, Lv, Liu, Cao, Du, Li, Li, Luo and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).74

Nanotherapeutic Strategies

CXCR4-targeted nanotherapeutics represent a promising approach for treating LF and HCC by targeting the CXCR4 receptor, which plays a crucial role in liver disease progression and cancer metastasis. The CXCR4 receptor is highly expressed on HSCs involved in fibrosis, as well as on tumor cells in HCC.¹⁸ NPs designed to target CXCR4 can deliver therapeutic agents, such as small molecules, siRNA, or immune modulators, directly to these cells, enhancing the specificity and efficacy of treatment. These targeted nanocarriers improve drug bioavailability at the site of action while minimizing off-target effects.

For LF, CXCR4-targeted NPs can be used to modulate the activation of HSCs, which are responsible for ECM remodeling and fibrosis progression.⁴⁴ In HCC, these nanotherapeutics can inhibit CXCR4 signaling axis, preventing tumor growth, metastasis, and angiogenesis, thereby enhancing the response to chemotherapy or immunotherapy.⁷⁵ Additionally, the incorporation of stimuli-responsive materials in CXCR4-targeted nanocarriers can facilitate controlled drug release within the TME, optimizing therapeutic outcomes.⁷⁵ Overall, CXCR4-targeted nanotherapeutics offer a novel and effective strategy for treating LF and HCC, improving therapeutic precision, and reducing systemic toxicity.

Nanoparticle-Based Systems

Liposomes

Liposomes are emerging as effective nanotherapeutic carriers for LF and HCC due to their ability to encapsulate therapeutic agents and target liver-specific cells. These nanocarriers enhance drug delivery by improving solubility, controlling release, and minimizing systemic toxicity.⁷⁶ In LF and HCC, liposomes can target HSCs and tumor tissues, offering a promising strategy for more efficient and targetted treatment. Liu et al designed liposomal NPs to target HSCs by incorporating AMD3100 and VEG siRNA to combat the progression of LF. They engineered a core complex through the protamine-mediated condensation of VEGF siRNA, which was subsequently encapsulated within anionic liposomes. AMD3100-surface modification enabled CXCR4-targeted delivery, whereas DSPE-PEG incorporation into the lipid bilayer enhanced the systemic circulation time. In a CCl4-induced murine LF model, the administration of multifunctional liposomes demonstrated significant antifibrotic efficacy by simultaneously inhibiting HSCs activation and proliferation through CXCR4 blockade and suppressing angiogenesis via VEGF silencing. This dual-mechanism approach highlights the potential of CXCR4 receptor-targeted nanocarriers for combinatorial therapy of hepatic fibrosis (Figure 9 and Table 1).⁴¹

Figure 9 A schematic representation of the design and mechanism of CXCR4 antagonist-functionalized NPs for targeted delivery to HSCs. The NPs are composed of liposomes modified with CXCR4 antagonist, VEGF siRNA, and DSPE-PEG for enhanced targeting and stability. Upon interaction with the CXCR4 receptor on HSCs, the NPs undergo receptor-mediated endocytosis, releasing VEGF siRNA to downregulate VEGF expression, thereby inactivating the HSCs and reducing fibrosis progression.

Sorafenib treatment paradoxically activates the CXCL12/CXCR4 axis, worsening intra-tumoral hypoxia, promoting tumor progression, metastasis, immunosuppression, and contributing to therapeutic resistance in HCC.⁷⁷ To address this, a multifunctional oxygen-releasing nanoplatform (PFH@LSLP) was developed, featuring a perfluorohexane (PFH) core encapsulated in LFC131 peptide-functionalized liposomes. This system co-delivers the CSF1/CSF1R inhibitor PLX3397 (pexidartinib) and sorafenib, offering a synergistic approach to overcoming sorafenib resistance through three key mechanisms: (1) PFH core provides sustained oxygen release, alleviating hypoxia, (2) LFC131 peptides block the CXCL12/CXCR4 axis, restoring drug sensitivity, and (3) PLX3397 reprograms TAMs, enhancing CD8+ T-cell infiltration and counteracting immunosuppression. In preclinical models, including H22 tumor-bearing mice and HCC patient-derived xenografts, PFH@LSLP demonstrated significant anti-tumor efficacy by simultaneously modulating hypoxia, resistance pathways, and the TME. The PFH@LSLP nanoplatform offers a promising strategy to overcome sorafenib resistance in HCC by simultaneously addressing intra-tumoral hypoxia, blocking the CXCL12/CXCR4 axis, and reprogramming TAMs thus enhancing immune responses and improving therapeutic outcomes in sorafenib-resistant HCC. This approach establishes a novel paradigm for overcoming sorafenib resistance in HCC through integrated nanotherapeutic strategies. (Figure 10 and Table 1).⁷⁸

Figure 10 Illustration of mechanism of PFH@LSLP-mediated synergistic therapy for sorafenib-resistant tumors by targeting CXCR4-overexpressing cells to alleviate tumor hypoxia and immunosuppression. The PFH@LSLP NPs, loaded with PFH, sorafenib, and PLX3397, enhance tumor cell apoptosis by reducing SDF-1α and HIF-1α expression. This treatment also promotes immune activation by inhibiting CSF1/CSF1R signaling, leading to the polarization of TAMs and the secretion of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-10. Additionally, the therapy activates CD8+ T and CD4+ T cells, boosting the anti-tumor immune response. This combination approach overcomes sorafenib resistance, improves tumor immunogenicity, and enhances the overall efficacy of immunotherapy. Wang Y, Wang Z, Jia F, Xu Q, Shu Z, Deng J, Li A, Yu M, Yu Z. CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment. Bioact Mater. 2022 Jan 20;17:147–161. doi: 10.1016/j.bioactmat.2022.01.003. PMID: 35386453; PMCID: PMC8965090. © 2022 The Authors. This is an open access article under the CC BY-NC-ND license CC BY-NC-ND 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).78

HCC remains a leading cause of cancer-related mortality, with limited therapeutic options for advanced-stage disease. While PD-1 inhibitors, such as pembrolizumab and nivolumab, have demonstrated clinical efficacy, their effectiveness is often hindered by the immunosuppressive TME, particularly the hypoxia-driven activation of the CXCL12/CXCR4 axis. To address this limitation, a recent study introduced 807-lipid-coated tannic acid NPs encapsulating BPRCX807, a potent CXCR4 antagonist, as a targeted therapeutic approach for HCC. These NPs improved the pharmacokinetic profile and tumor-specific delivery of BPRCX807, reducing systemic toxicity. Mechanistically, 807-NPs disrupted the CXCR4/CXCL12 signaling pathway, inhibiting Akt and mTOR activation in both M2-polarized macrophages and HCC cells, thereby promoting their repolarization to an immunostimulatory M1 phenotype. In HCC xenograft models, treatment with 807-NPs reprogrammed the immunosuppressive TME, shifting TAMs toward a pro-inflammatory state and increasing the infiltration of cytotoxic T cells. This resulted in significant reductions in tumor growth and metastasis. Furthermore, 807-NPs enhanced the efficacy of immunotherapeutic strategies, including PD-1 blockade and cancer cell vaccines, by boosting T-cell activation. In conclusion, the use of lipid-coated tannic acid NPs encapsulating CXCR4 antagonists represents a novel and effective strategy to target the immunosuppressive TME in HCC. These NPs enhance the tumor-specific delivery of therapeutic agents, reduce systemic toxicity, and synergize with immunotherapies, thereby improving the overall efficacy of HCC treatment (Figure 11 and Table 1).⁷⁵

Figure 11 Mechanism of Action of 807-NPs in HCC. The 807-NP platform delivers the CXCR4 antagonist BPRCX807 to HCC tumors, effectively disrupting the CXCR4/CXCL12 signaling axis. This inhibition suppresses Akt/mTOR signaling in both HCC cells and M2-polarized bone marrow-derived macrophages (BMDMs), leading to the repolarization of immunosuppressive M2 macrophages into an antitumor M1 phenotype. In orthotopic HCC models, systemic treatment with 807-NPs reprograms TAMs to an immunostimulatory state, enhancing cytotoxic T-cell infiltration and significantly inhibiting primary tumor growth and metastasis. Furthermore, 807-NPs synergize with immunotherapies, including PD-1 blockade and whole-cell cancer vaccines, to promote intratumoral T-cell proliferation and activation, leading to substantial suppression of tumor progression. Sheng-Liang Cheng, Chien-Huang Wu, Yun-Jen Tsai, Jen-Shin Song, Hsin-Min Chen, Teng-Kuang Yeh, Chia-Tung Shen, Jou-Chien Chiang, Hsin-Mei Lee, Kuan-Wei Huang, Yuling Chen, J Timothy Qiu, Yu-Ting Yen, Kak-Shan Shia, Yunching Chen. CXCR4 antagonist-loaded NPs reprogram the TME and enhance immunotherapy in hepatocellular carcinoma, Journal of Controlled Release, Volume 379, 2025, Pages 967–981, ISSN 0168–3659, © 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.75

Microbubbles

Microbubbles (MBs) have emerged as an innovative class of nanotherapeutics with great potential for treating LF and HCC.⁷⁹ These gas-filled particles, typically used in conjunction with ultrasound, offer unique advantages in terms of targeted drug delivery and non-invasive imaging.⁸⁰ When functionalized with ligands that target specific receptors, such as CXCR4 on HSCs or TAMs, MBs can selectively deliver therapeutic agents directly to the liver, improving their localized effectiveness while minimizing systemic exposure. Ultrasound molecular imaging has emerged as a cutting-edge modality that integrates ultrasound technology with molecular probes to enable the real-time visualization of cellular and molecular processes in vivo. CXCR4, a key regulator of tumor progression, angiogenesis, and metastasis in hepatic malignancies, has been identified as a promising target for molecular imaging and therapeutic intervention. Recent advancements have demonstrated that CXCR4-targeted MBs exhibit exceptional ligand conjugation efficiency (99.77 ± 0.15%) in vascular endothelial cells, while effectively suppressing Hepa1-6 cell migration and invasion. Preclinical studies in Hep G2 tumor-bearing BALB/c mice revealed that LFC131 peptide-conjugated MBs enabled precise tumor localization through contrast-enhanced ultrasound (CEUS) imaging, with a marked reduction in imaging signal intensity following chemotherapy compared to conventional SonoVue MBs, supported by immunohistochemical quantification of CXCR4 expression. Notably, combinatorial immunotherapy employing anti-PD-L1 monoclonal antibodies with CXCR4-targeted MBs achieved a potent antitumor response (94.6% inhibition rate), characterized by enhanced CD8+ T-cell infiltration and diminished FOXP3+ regulatory T-cell presence. Transcriptomic profiling and in vivo validation further confirmed that this synergistic approach elicited robust immunomodulatory effects in HCC cells. These insights not only underscore the diagnostic potential of CXCR4-directed molecular ultrasound but also provide a strategic framework for enhancing therapeutic efficacy in liver cancer management (Figure 12 and Table 1).⁸¹

Figure 12 A schematic illustration of the experimental design for CXCR4-targeted MBs in liver cancer treatment. (A) CXCR4-targeted MBs are synthesized by functionalizing with biotinylated LFC131 peptides. (B) CEUS imaging is conducted in orthotopic liver tumor-bearing nude mice, where intravenous injection of the CXCR4-targeted MBs enables their adhesion to the tumor vasculature and circulation within the bloodstream. (C) The application of CXCR4-targeted MBs involves ultrasound imaging and sensitization of immunotherapy for liver cancer. (D) CXCR4-targeted MBs enhance the efficacy of liver cancer immunotherapy, improving treatment outcomes. Yi-Jie Qiu, Jia-Ying Cao, Jing-Han Liao, Yi Duan, Sheng Chen, Rui Cheng, Yun-Lin Huang, Xiu-Yun Lu, Juan Cheng, Wen-Ping Wang, You-Rong Duan, Yi Dong. CXCR4-targeted ultrasound microbubbles for imaging and enhanced chemotherapy/Immunotherapy in liver cancer, Acta Biomaterialia, Volume 197, 2025, Pages 416–430, ISSN 1742–7061, https://doi.org/10.1016/j.actbio.2025.03.018. © 2025 Acta Materialia Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.81

Polymeric NPs

CXCR4-targeted polymeric NPs have emerged as effective nanotherapeutics for LF and HCC due to their ability to deliver drugs with high specificity and controlled release. These NPs can be engineered to target key cells involved in fibrogenesis and tumor progression, such as HSCs and TAMs.⁴⁴ By enhancing drug bioavailability within the liver and minimizing off-target effects, polymeric NPs offer a promising strategy for improving treatment outcomes in both fibrotic liver disease and cancer. Sung et al developed a novel CXCR4-targeted NP system by co-formulating AZD6244, a MEK inhibitor, and sorafenib in lipid-coated poly(lactic-co-glycolic acid) (PLGA) NPs modified with CTCE9908, a CXCR4-antagonist peptide. This innovative system enables the co-delivery of sorafenib (SOR) and AZD6244, achieving dual pathway inhibition through two mechanisms: (1) the direct antifibrotic action of SOR and (2) the suppression of compensatory MAPK activation and CXCL12/CXCR4 axis by AZD6244. In both in vitro and in vivo models of LF induced by CCl₄, this combinatorial approach effectively inhibited the activation of HSCs, reduced fibrogenesis, and prevented the progression of LF to HCC. The CXCR4-targeted delivery system significantly enhanced the bioavailability of the drugs to activated HSCs, offering a more precise and efficient therapeutic strategy for treating LF and its associated complications, such as HCC. This approach highlights the potential of combining CXCR4-targeted delivery with dual pathway inhibition to improve treatment outcomes in LF and HCC (Figure 13 and Table 1).⁴⁴

Figure 13 A schematic illustration of the impact of SOR and MEK inhibitor treatments on fibrotic liver progression. In the untreated fibrotic liver (left panel), signaling through PDGFR, CXCR4, and downstream pathways (Ras, PI3K, AKT, MEK, and ERK) promotes collagen production, HSCs activation, and HCC development. In the low-dose SOR treatment (middle panel), SOR paradoxically activates ERK and increases the activation of NF-κB expression, which increases α-SMA expression and the production of collagen in HSCs.. In the combination treatment (right panel), SOR and the MEK inhibitor AZD6244, when co-formulated in CTCE9908-NPs, suppressed ERK activation and inhibited HSC activation, enhancing the anti-fibrotic and cancer prevention effect in a murine model of liver damage.Arrows indicate increased signaling (↑), and decreased signaling (↓) highlighting the therapeutic potential of the combined treatment. Sung YC, Liu YC, Chao PH, Chang CC, Jin PR, Lin TT, Lin JA, Cheng HT, Wang J, Lai CP, Chen LH, Wu AY, Ho TL, Chiang T, Gao DY, Duda DG, Chen Y. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted NPs reduces hepatic fibrosis and prevents tumor development. Theranostics. 2018 Jan 1;8(4):894–905. doi: 10.7150/thno.21168. PMID: 29463989; PMCID: PMC5817100. © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/) © Ivyspring International Publisher.44

Inorganic NPs

Inorganic NPs are gaining attention for their potential in managing LF and HCC due to their unique physicochemical properties, such as stability, high surface area, and ease of functionalization. These NPs, including gold, silica, and iron oxide NPs, can be engineered for targeted drug delivery, enabling precise treatment of liver diseases while minimizing off-target effects.⁸² Their ability to incorporate therapeutic agents, such as chemotherapeutic drugs or siRNA, allows for enhanced therapeutic efficacy and improved bioavailability at the disease site.⁸³ A multifunctional CXCR4-inhibiting nanocomplex, PA-Zn-CLD/siPAI-1, combines polymeric CXCR4 antagonism (PAMD, PA), clodronate (CLD), and siRNA targeting plasminogen activator inhibitor-1 (siPAI-1) to enhance HSCs-targeted delivery by mitigating KC uptake, ECM entrapment, and non-specific HSCs recognition. Comparative analysis with nanocomplexes (PA-Zn/siScr, PA-Zn/siPAI-1, and PA-Zn-CLD/siScr) confirmed the superior HSCs-targeting efficiency of PA-Zn-CLD/siPAI-1, which was attributed to the synergistic effects of PA-mediated HSCs recognition, CLD-induced KC apoptosis, and siPAI-1-driven ECM degradation. The nanocomplex exhibited preferential liver accumulation and demonstrated enhanced antifibrotic efficacy through coordinated modulation of KC depletion, ECM remodeling, and HSCs inactivation. These findings highlight its potential as a robust HSCs-targeted delivery platform for LF treatment (Figure 14 and Table 1).⁸⁴

Figure 14 A schematic illustration the fabrication and mechanism of the CXCR4-inhibiting nanocomplex. (a) The molecular architecture of PA-Zn-CLD and the assembly process for the PA-Zn-CLD/siPAI-1 nanocomplex. (b) The mechanism through which the nanocomplex overcomes biological barriers in LF therapy: CLD overcomes KC capture, siPAI-1 facilitates ECM degradation, and PA ensures effective HSCs uptake. This coordinated action leads to enhanced antifibrotic activity and liver function recovery. Pengkai Wu, Xinping Luo, Meiling Sun, Beicheng Sun, Minjie Sun, Synergetic regulation of kupffer cells, ECMand HSCswith versatile CXCR4-inhibiting nanocomplex for magnified therapy in LF, Biomaterials, Volume 284, 2022, 121492, ISSN 0142–9612, © 2022 Published by Elsevier Ltd.84

Natural Polysaccharide-Based Smart CXCR4-Targeted Nano-System

Natural polysaccharide-based smart targeted nanocarriers have emerged as an innovative approach for managing LF and HCC. These nanocarriers leverage the biocompatibility and biodegradability of polysaccharides, offering controlled drug release and enhanced targeting efficiency. By functionalizing these systems with specific ligands or stimuli-responsive elements, they can selectively deliver therapeutic agents to the liver, improving treatment precision and minimizing off-target effects.^85,86 The CXCR4 targeted reactive oxygen species (ROS)-responsive platform AMD-Dex-ROS-responsive-sorafenib (ARS) NPs, constructed from a biocompatible polysaccharide and thioctic acid-derived framework, demonstrated high delivery efficiency and selective pharmacological effects on HSCs. By targeting the CXCR4 receptor, this system effectively antagonizes the CXCL12/CXCR4 axis, while enabling on-demand drug release. The incorporation of AMD3100 facilitates specific HSCs targeting and disrupts CXCL12/CXCR4 axis mediated HSCs survival mechanisms, whereas the ROS-responsive thioctic acid crosslinker ensures controlled drug delivery. Sorafenib, a primary therapeutic agent, promotes HSCs apoptosis, resulting in a robust anti-fibrotic effect. The CXCR4-targeted ARS NPs provide an innovative and effective approach for treating LF. By targeting HSCs and utilizing on-demand drug release, this system significantly enhances therapeutic precision and antifibrotic efficacy. Moreover, the platform offers a versatile foundation for the integration of additional anti-fibrotic agents, further advancing the potential for targeted fibrosis therapies. (Figure 15 and Table 1).⁸⁶

Figure 15 A schematic illustration of the anti-fibrotic effects of Sorafenib and AMD3100 co-delivery in LF. In the upper panel, Dex-RTA self-assembles into nanostructures, with AMD3100 and Sorafenib electrostatically adsorbed to form the RS and ARS formulations. In the lower panel, the ARS treatment in a fibrotic liver model shows that the combination of Sorafenib and AMD3100 promotes HSCs apoptosis, reduces HSC activation, α-SMA expression, and ECM deposition, leading to significant anti-fibrotic effects. Liqiong Sun, Xinping Luo, Chenxi Zhou, Zhanwei Zhou, Minjie Sun, Natural polysaccharide-based smart CXCR4-targeted nano-system for magnified LF therapy, Chinese Chemical Letters, Volume 35, Issue 2, 2024, 108803, ISSN 1001–8417, © 2023 Published by Elsevier B.V. on behalf of Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences.86

Gao et al developed CXCR4 targeted lipid-coated PLGA NPs (ADOPSor NPs) modified with AMD3100 to co-deliver sorafenib and AMD3100 to block the CXCL12/CXCR4 axis in HCC. Although sorafenib monotherapy shows limited efficacy owing to hypoxia-induced CXCL12/CXCR4 axis activation and TME polarization, these multifunctional NPs demonstrate dual therapeutic mechanisms: (1) CXCR4-targeted sorafenib delivery to achieve cytotoxic and anti-angiogenic effects in HCC and endothelial cells, and (2) CXCL12/CXCR4 axis inhibition via surface-conjugated AMD3100 to counteract drug resistance. In orthotopic HCC models, NPs significantly reduced TAM infiltration, enhanced anti-angiogenesis, delayed tumor progression, and improved survival compared with controls. These findings highlight the potential of CXCR4-targeted NPs to overcome sorafenib resistance and enhance anti-tumor effects through coordinated drug delivery and microenvironment modulation. This approach offers a promising strategy for HCC therapy, showcasing the clinical potential of multifunctional nanocarriers that combine tumor targeting with microenvironment reprogramming for improved cancer treatment (Figure 16 and Table 1).⁵⁹

Figure 16 A schematic illustration of the mechanism of Sorafenib delivery via ADOPSor NPs in liver cancer. The ADOPSor NPs, which co-deliver Sorafenib, target both endothelial cells and HCC cells. In the endothelial cells (upper right panel), Sorafenib blocks VEGFR/PDGFR and CXCR4 signaling, inhibiting angiogenesis by preventing Ras-RAF-MEK-ERK activation. In the HCC cells (lower right panel), Sorafenib inhibits HCC cell proliferation and survival by targeting growth receptors and the CXCR4 axis, also suppressing the Ras-RAF-MEK-ERK pathway. Dong-Yu Gao, Ts-Ting Lin, Yun-Chieh Sung, Ya Chi Liu, Wen-Hsuan Chiang, Chih-Chun Chang, Jia-Yu Liu, Yunching Chen, CXCR4-targeted lipid-coated PLGA NPs deliver sorafenib and overcome acquired drug resistance in liver cancer, Biomaterials, Volume 67, 2015, Pages 194–203, ISSN 0142–9612. Copyright © 2015 Elsevier Ltd. All rights reserved.59

Peptide NPs

Peptide-functionalized NPs are emerging as promising tools for managing liver fibrosis and HCC.⁸⁷ These NPs are designed to specifically target liver cells, including activated HSCs, using peptides that bind to CXCR4.⁸⁸ By delivering therapeutic agents directly to the target cells, peptide NPs enhance drug efficacy, minimize off-target effects, and offer a precise strategy to modulate fibrogenesis and inhibit tumor progression. The liver-targeted drug CX-EPNP, composed of PLGA/TPGS NPs surface-coupled with the LFC131 peptide, was successfully developed to enhance the targeted delivery of epirubicin (EPI) to CXCR4-overexpressing liver tumors. The CX-EP NPs exhibited sustained-release kinetics, demonstrating their suitability for cancer-targeting. In vitro studies revealed a 3-fold increase in cellular uptake by HepG2 cells compared to non-targeted NPs. The CX-EP NPs showed significant cytotoxicity and increased apoptosis. In vivo, the CX-EP NPs showed prolonged blood circulation (>24 h), preferential tumor accumulation, and evasion of KCs clearance, suggesting effective tumor suppression with reduced systemic side effects (Figure 17 and Table 1).⁸⁹ The CX-EPNP system, incorporating CXCR4-targeting peptides, enhances the targeted delivery of EPI to liver tumors, demonstrating increased cellular uptake, potent tumor suppression, and reduced systemic toxicity. This approach offers promising therapeutic potential for liver cancer treatment.

Figure 17 Time-dependent uptake and cell viability analysis of EPNP and CX-EPNP in HepG2 liver cancer cells reveal enhanced internalization and greater cytotoxicity of CX-EPNP compared to EPNP at various concentrations (A) Intracellular uptake of EPNP and CX-EPNP in HepG2 cells at various time points (0.5–24h), showing higher NP internalization in the CX-EPNP group (*p < 0.05). Confocal images (bottom) show efficient uptake with rhodamine-B (red) and DAPI (blue) (B) Cell viability of HepG2 cells after treatment with free EPI, EPNP, and CX-EPNP for 24h and 48h. CX-EPNP significantly reduced cell viability compared to EPNP (*p < 0.05), indicating enhanced therapeutic efficacy. Sun Di-Wen, Guo-Zheng Pan, Long Hao, Jian Zhang, Qing-Ze Xue, Peng Wang, Qing-Zhong Yuan. Improved antitumor activity of epirubicin-loaded CXCR4-targeted polymeric NPs in liver cancers. International Journal of Pharmaceutics. Volume 500, Issues 1–2, 2016,Pages 54–61, ISSN 0378–5173. Copyright © 2016 Elsevier B.V. All rights reserved.89

Iron Oxide NPs

Iron oxide NPs can be functionalized to target HSCs, enabling precise drug delivery and enhanced therapeutic efficacy. Additionally, iron oxide NPs can be utilized for both diagnostic (imaging) and therapeutic applications, offering a multifunctional approach to liver disease treatment.⁹⁰ The nanoplatform (FDAH NPs) consisted of an iron-based core encapsulated with AMD3100 and DOX coated with an HA shell to extend circulation and enable CD44-targeted delivery. Upon uptake by tumor cells, iron ions mediate chemodynamic therapy (CDT) via Fenton reaction-generated ROS, disrupting redox homeostasis and sensitizing cells to DOX. Simultaneously, AMD3100 inhibits the CXCL12/CXCR4 axis, alleviates immunosuppression, and enhances chemotherapy efficacy. In vitro and in vivo studies have demonstrated synergistic tumor suppression through the combination of CDT, chemotherapy, and immunomodulation. This strategy presents a promising approach to overcoming chemoresistance and improving therapeutic outcomes in HCC by integrating targeted drug delivery, redox modulation, and immune microenvironment remodeling (Figure 18 and Table 1).⁹¹

Figure 18 Optimizing HA-decorated ferric-based metal-organic-framework (MOF) named FDAH Therapy for HCC: Augmenting Synergistic Chemo/Chemodynamic Efficacy Through Tumor Immunomodulation. Guo C, Dou R, Wang L, Zhang J, Cai X, Tang J, Huang Z, Liu X, Chen J, Chen H. A metal-drug self-delivery nanomedicine alleviates tumor immunosuppression to potentiate synergistic chemo/chemodynamic therapy against hepatocellular carcinoma. Fundam Res. 2024 Dec 30;5(4):1440–1450. doi: 10.1016/j.fmre.2024.12.014. PMID: 40777784; PMCID: PMC12327863. © 2024 The Authors. Publishing Services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY-NC-ND license.91

Clinical Advances

Monoclonal Antibodies Targeting CXCR4

Monoclonal antibodies directed against CXCR4 have emerged as promising therapeutic candidates in cancer and other disease contexts, owing to their ability to selectively target CXCR4. CXCR4 is implicated in critical pathological processes including cellular migration, proliferation, and survival, and its overexpression is frequently observed in malignant cells. By antagonizing CXCR4 signaling, these antibodies exhibit the potential to impair tumor progression through multiple mechanisms, including suppression of cancer cell proliferation, inhibition of metastatic dissemination, and modulation of immune evasion pathways.⁹² Numerous monoclonal antibodies (mAbs) have been directed against CXCR4 in tumors. Among these, ulocuplumab (BMS-936564/MDX-1338), a fully humanized IgG4 mAb developed by Bristol Myers Squibb, has shown promising efficacy in animal models of hematological malignancies and solid tumors.⁹³ Additional anti-CXCR4 mAbs in development include PF-06747143 (Pfizer), a humanized IgG1 antibody^94,95 LY2624587 (Eli Lilly), a recombinant humanized mAb;⁹⁵ and F50067 (Hz515H7) (Pierre Fabre SA), an IgG1 mAb primarily investigated in early phase clinical trials for hematologic cancers (Table 2).⁹⁶

Table 1 CXCR4-Targeted Nanodelivery Systems in Liver Disease and Cancer

Table 2 CXCR4-Targeting Therapeutics in Cancer and Fibrotic Diseases

In addition to conventional mAbs, protein engineering has enabled the development of novel antibody-based therapeutics. ALX-0651 (Ablynx, Inc.) is a biparatopic anti-CXCR4 nanobody (VHH) designed for stem cell mobilization.⁹⁷ Another innovative approach involves AD-214 (AdAlta), an Fc-fusion protein composed of two AD-114 i-body domains that target CXCR4 linked to an Fc fragment. This construct has shown promising pharmacokinetic, tolerability, and safety profiles in phase 1 trials for fibrotic diseases including interstitial lung disease (ILD) and CKD (Table 2).⁹⁸

The mAbs such as ulocuplumab can be used to inhibit HCC progression by suppressing tumor cell proliferation and metastasis to the liver. Furthermore, the anti-fibrotic potential demonstrated by constructs such as the AD-214 i-body in lung and kidney diseases suggests a direct pathway for combating hepatic fibrosis. The development of novel formats, such as biparatopic nanobodies, may offer improved tissue penetration to effectively modulate the pathogenic liver microenvironment.

In conclusion, mAbs targeting CXCR4, including both conventional and engineered formats like biparatopic nanobodies and Fc-fusion proteins, offer significant therapeutic potential for treating various cancers, including HCC, and fibrotic diseases (LF). These innovative therapeutics can impair tumor progression, enhance immune responses, and offer new strategies for addressing hepatic fibrosis, highlighting their versatile role in oncology and beyond.

Plerixafor as a CXCR4 Antagonist

Plerixafor acts as a chemosensitizer by promoting stem cell mobilization, thereby enhancing the exposure of malignant cells to chemotherapy. This mechanism has been explored in hematologic malignancies, including acute and chronic lymphocytic leukemia, myeloid leukemia, myelodysplastic syndrome, and multiple myeloma. In addition to its applications in hematologic cancers, plerixafor is being investigated in solid tumors, with ongoing clinical trials assessing its efficacy in combination with checkpoint inhibitors. Notably, a Phase 2 trial (NCT04177810) evaluated plerixafor in combination with the anti-PD1 agent cemiplimab in metastatic pancreatic cancer.⁹⁹ Furthermore, plerixafor has demonstrated the ability to penetrate the blood-brain barrier (BBB) and has shown an established safety profile when co-administered with anti-VEGF therapy in high-grade glioma patients. Its potential in glioblastoma is further explored in a phase 2 clinical trial (NCT03746080) combining plerixafor with standard temozolomide chemoradiotherapy. As the most extensively studied CXCR4 antagonist, plerixafor has been evaluated in over 150 registered clinical trials, primarily focused on hematologic cancers.¹⁸ In conclusion, plerixafor, with its well-established stem cell-mobilizing properties, shows promising preclinical and clinical potential beyond hematologic malignancies. Its mechanism, which disrupts the CXCL12/CXCR4 axis, aligns with key pathways in hepatic fibrogenesis and TME modulation, as demonstrated by its ability to reduce liver injury, portal hypertension, and fibrosis progression in rodent models. Further investigation in LF and HCC is warranted (Table 2).

Motixafortide (BL-8040) as a CXCR4 Antagonist

Motixafortide (BL-8040), a CXCR4 antagonist, was evaluated in a phase IIa open-label trial (NCT02826486) examining its combination with pembrolizumab in metastatic pancreatic cancer. In Cohort 1 (n=37, chemo-resistant), the combination achieved a 34.5% disease control rate, including 1 partial response and 9 cases of stable disease, with a median overall survival (OS) of 3.3 months, extending to 7.5 months in second-line patients. Cohort 2 (n=22) received chemotherapy and demonstrated a 32% objective response rate and 77% disease control, with a median response duration of 7.8 months. Immunological analyses revealed an increase in tumor CD8+ T cells and a reduction in immunosuppressive cells. The combination showed promising clinical activity, especially when used with chemotherapy, and demonstrated an acceptable safety profile, suggesting the need for further randomized trials in pancreatic cancer.¹⁰⁰ Given the role of CXCR4 in fibrogenesis, tumor progression, and immune evasion within the liver microenvironment, motixafortide warrants further investigation in LF and HCC. It may offer potential therapeutic benefits by remodeling the immunosuppressive TME, possibly synergizing with checkpoint inhibitors and other targeted therapies (Table 2).

tpdelPTX-9908 (CTCE-9908), a CXCL12-derived peptide antagonist targeting CXCR4, has demonstrated significant anti-tumor and anti-metastatic effects in preclinical models. PTX-9908 has been evaluated by TCM biotech in a phase 1/2 trial (NCT03812874) as an adjuvant therapy for unresectable HCC following transarterial chemoembolization (TACE) to prevent recurrence. TCM Biotech also explored its potential in combination with immune checkpoint inhibitors, signaling a strategic shift towards immuno-oncology applications. These trials aim to assess its therapeutic efficacy in HCC, its safety profile, and its synergistic effects when combined with existing treatments. Further studies may investigate its application in other malignancies driven by CXCR4 signaling.¹⁸ PTX-9908’s ability to inhibit tumor-associated angiogenesis and metastasis, processes similar to those involved in fibrosis progression through CXCL12/CXCR4 signaling, suggests its potential for treating LF and HCC. A phase 1/2 trial could evaluate its safety and efficacy in halting or reversing fibrogenesis, particularly in patients with progressive fibrosis that are unresponsive to standard treatments. The trial may include biomarkers such as hydroxyproline or α-SMA reduction as endpoints, reflecting the antifibrotic effects observed in CXCR4-targeting nanomedicine studies. PTX-9908 holds promise as both a therapeutic agent for HCC and a potential treatment for LF, with its ability to inhibit tumor progression and fibrogenesis (Table 2).

Challenges and Biological Barriers

Off-Target Hematopoietic Toxicity of CXCR4 Targeting: Molecular Mechanisms and Nanotechnology-Guided Solutions

CXCR4 is a master regulator of hematopoietic stem cell (HSC) trafficking, retention, and survival within the bone marrow (BM) niche through tight coordination with CXCL12 gradients produced by MSCs, osteoblasts, and endothelial niche components.^101,102 At the molecular level, CXCL12–CXCR4 engagement activates multiple downstream survival and quiescence signaling pathways, including PI3K/AKT, MAPK/ERK, JAK/STAT, and focal adhesion kinase (FAK) cascades.¹⁰³ These signaling networks collectively regulate cytoskeletal organization, integrin activation (VLA-4/VCAM-1 axis), mitochondrial homeostasis, and anti-apoptotic signaling through BCL-2 family proteins, thereby maintaining HSC dormancy and long-term repopulation potential.¹⁰⁴ Systemic inhibition of CXCR4 disrupts these regulatory networks, leading to rapid HSC mobilization through destabilization of CXCR4-dependent adhesion complexes and suppression of stromal survival signaling.¹⁰⁵ Loss of stromal CXCR4 signaling reduces MSC survival and decreases secretion of key hematopoietic cytokines, including SCF (Stem Cell Factor), TPO (Thrombopoietin), and IL-7 (Interleukin-7), ultimately impairing hematopoietic stem and progenitor cell (HSPC) quiescence and self-renewal. During myeloablative stress, CXCR4 deficiency exacerbates stromal apoptosis through impaired PI3K–AKT survival signaling and increased caspase-mediated cell death, resulting in delayed niche regeneration and compromised hematopoietic recovery.¹⁰⁶ Transplantation studies further demonstrate that CXCR4-deficient BM microenvironments exhibit impaired homing efficiency due to reduced expression of adhesion molecules and ECM retention factors, highlighting the central role of niche-derived CXCR4 signaling in post-injury hematopoietic reconstitution.^84,106,107

From a translational perspective, selective spatial and temporal control of CXCR4 inhibition is essential to preserve BM niche integrity while maintaining therapeutic efficacy in LF and HCC. Recently developed nanoplatforms provide a mechanistically rational strategy to achieve localized CXCR4 modulation while minimizing systemic hematopoietic toxicity. CXCR4-targeted liposomal systems, including AMD3100-functionalized liposomes and oxygen-responsive PFH@LSLP nanoplatforms, enable targeted inhibition of CXCR4 signaling specifically within fibrotic hepatic tissue or TME.⁷⁸ These systems limit systemic CXCR4 blockade while simultaneously modulating hypoxia-driven HIF-1α stabilization, which is known to upregulate CXCL12 expression and promote tumor immune evasion. Similarly, lipid-coated tannic acid NPs encapsulating CXCR4 antagonists suppress downstream AKT/mTOR signaling in TAMs and HCC cells, promoting macrophage repolarization toward pro-inflammatory M1 phenotypes while preserving systemic immune and hematopoietic function (Figure 9–11).⁷⁵ CTCE9908-modified PLGA NPs, offer dual pathway inhibition by simultaneously blocking CXCR4 signaling and suppressing pro-fibrotic TGF-β/SMAD signaling or MAPK-driven compensatory fibrogenic pathways which effectively suppress HSCs activation by downregulating α-SMA, collagen I, and TIMP expression, while minimizing systemic CXCR4 inhibition due to preferential accumulation within activated HSCs populations (Figure 13).¹⁸

Inorganic and hybrid nanocomplexes including PA-Zn-CLD/siPAI-1 systems and dual-function CXCR4 inhibitor/miRNA-targeting NPs, demonstrate multi-barrier penetration capability by overcoming KC uptake, ECM entrapment, and non-specific hepatic clearance. These systems facilitate localized ECM remodeling through PAI-1 suppression and plasmin activation while maintaining spatially restricted CXCR4 antagonism. Importantly, dual-pathway inhibition strategies combining VEGF silencing with CXCR4 blockade restore vascular normalization and reduce hypoxia-induced fibrogenic signaling (Figure 14).⁸⁴

Natural polysaccharide-based smart nanocarriers offer controlled drug release and enhanced targeting for LF and HCC treatment. The CXCR4-targeted ROS-responsive ARS NPs selectively deliver drugs to HSCs, enhancing therapeutic precision. This system disrupts the CXCL12/CXCR4 axis, promoting apoptosis and offering potential for integrating additional anti-fibrotic agents. (Figure 15).⁸⁶ Similarly, CXCR4-targeted PLGA nanocarriers delivering sorafenib (Figure 16) overcome hypoxia-induced CXCR4 upregulation and tumor immune evasion by reducing TAMs infiltration and suppressing angiogenic VEGF signaling.⁵⁹

Peptide guided NPs system (Figure 17) carriers introduce an additional level of biological targeting precision through receptor-mediated endocytosis and chemokine-gradient-guided homing, respectively. These platforms enhance drug delivery efficiency while reducing systemic exposure and preserving physiological CXCR4 function in hematopoietic tissues.

Finally, theranostic nanoplatforms incorporating iron oxide cores (Figure 18) enable simultaneous CXCR4 inhibition, chemotherapy, and chemodynamic therapy via ROS generation, while also allowing real-time magnetic resonance imaging monitoring of drug biodistribution and therapeutic response. Such systems provide an integrated framework for precision dosing and early detection of off-target hematopoietic toxicity.¹⁰⁸

Future translational development should focus on integrating CXCR4-targeted nanomedicine with combination immunotherapy strategies, including immune checkpoint blockade and macrophage reprogramming therapies, to maximize tumor immunogenicity while minimizing systemic immune and hematopoietic disruption. In parallel, the incorporation of real-time monitoring technologies, such as molecular ultrasound and MRI-visible nanocarriers, will be essential for enabling adaptive therapeutic dosing and personalized treatment optimization.^18,109 Collectively, the integration of molecularly targeted nanocarriers, combination immunotherapy, and theranostic monitoring platforms represents a next-generation precision medicine strategy for safely translating CXCR4-targeted therapies into clinical applications for LF and HCC while preserving bone marrow niche integrity.

Immune Dysregulation & Infection Risk

Chronic CXCR4 blockade has been shown to disrupt essential immune functions, including B-cell development, neutrophil trafficking, and lymph node homing, thereby increasing susceptibility to infections.⁸⁴ In parallel, the CXCL12–CXCR4 signaling axis plays a critical regulatory role in inflammatory and vascular pathologies, including atherosclerosis, where dysregulated CXCR4 signaling promotes neutrophil hyperactivation, endothelial adhesion, and inflammatory plaque destabilization.¹¹⁰ These systemic observations are highly relevant to CLDs, where CXCR4 signaling contributes to immune cell recruitment, HSCs activation, angiogenesis, and fibrogenesis. However, prolonged systemic inhibition of CXCR4 may also disrupt hepatic immune surveillance and tissue repair mechanisms, potentially increasing infection risk and impairing liver regeneration in advanced disease states.

In LF, the CXCL12/CXCR4 axis mediates HSCs activation, ECM deposition, and inflammatory cell recruitment, making it an attractive therapeutic target.¹¹¹ Similarly, in HCC, CXCL12/CXCR4 signaling promotes tumor cell migration, angiogenesis, immune evasion, and resistance to systemic therapies such as sorafenib.¹¹² From a translational perspective, these dual roles highlight the need for disease-stage-specific and tissue-targeted therapeutic strategies. Rather than systemic CXCR4 suppression, emerging approaches focus on localized or conditional pathway modulation using multifunctional nanocarriers capable of co-delivering CXCR4 antagonists with antifibrotic, anti-angiogenic, or immunomodulatory agents. Such systems may allow selective targeting of activated HSCs, TAMs, or CXCR4-overexpressing tumor cells while preserving physiological CXCR4 signaling in healthy immune compartments.

Combination immunotherapy strategies also represent a promising translational direction in HCC. CXCR4 inhibition can enhance immune cell infiltration into tumors and reverse immunosuppressive TME, thereby improving responses to immune checkpoint blockade. For example, integrating CXCR4 antagonists with PD-1/PD-L1 inhibitors, macrophage reprogramming agents, or anti-angiogenic therapies may provide synergistic therapeutic benefits by simultaneously targeting tumor survival pathways and immune evasion mechanisms.^99,113 In fibrotic liver disease, similar combinatorial strategies may reduce fibrosis progression while restoring immune homeostasis.¹¹²

Importantly, the integration of real-time monitoring platforms could significantly enhance translational feasibility and clinical safety. CXCR4-targeted molecular imaging probes, CEUS MBs systems, and nanoparticle-based theranostic platforms may enable real-time assessment of drug biodistribution, receptor engagement, and therapeutic response. CXCR4-targeted MBs conjugated with LFC131 peptides demonstrate high targeting specificity, achieving a ligand binding efficiency of 99.77%, which contributes to effective suppression of tumor cell migration and enables accurate molecular imaging confirmed through immunohistochemical analysis. Furthermore, combining CXCR4-targeted MBs with anti-PD-L1 immunotherapy produced a substantial tumor inhibition rate of 94.6%, alongside increased infiltration of CD8⁺ cytotoxic T cells and a reduction in FOXP3⁺ regulatory T cells within the TME. These results highlight the potential of CXCR4-targeted MBs platforms to function as both diagnostic imaging tools and therapeutic sensitizers. Collectively, this strategy supports the development of molecular imaging-guided therapeutic approaches for improving treatment outcomes in liver cancer.⁸¹ These precision-guided approaches would support adaptive dosing strategies, reduce systemic toxicity, and improve patient selection for targeted therapy. Conclusively, the future clinical translation of CXCR4-targeted therapies in LF and HCC will likely depend on the convergence of targeted nanomedicine, combination immunotherapy, and real-time imaging-guided treatment strategies. Such integrated therapeutic platforms offer the potential to maximize antifibrotic and antitumor efficacy while minimizing systemic immune disruption, representing a promising direction for next-generation precision therapies in chronic liver disease and liver cancer.

Fibrotic Microenvironment Barriers

LSECs and excessive ECM deposition constitute major anatomical and biochemical barriers that restrict NPs extravasation and diffusion into fibrotic hepatic tissue, thereby limiting effective targeting of activated HSCs.¹¹⁴ Capillarization of LSECs, characterized by loss of fenestrations and basement membrane formation, further reduces nanocarrier translocation into the space of Disse.¹¹⁵ Concurrently, elevated oxidative stress within the fibrotic liver microenvironment promotes activation of multiple profibrotic signaling cascades, including TGF-β/Smad2/3, MAPK (p38, ERK1/2), PI3K/Akt/mTOR, and NF-κB pathways, which collectively drive HSCs transdifferentiation into myofibroblasts and enhance collagen I and α-SMA expression.¹¹⁶ Importantly, the CXCL12/CXCR4 axis acts as a central upstream regulator linking inflammatory recruitment, angiogenesis, and fibrogenesis through downstream activation of JAK/STAT3, PI3K/Akt, and ERK signaling, while also contributing to immune cell trafficking and macrophage polarization within the fibrotic niche.¹¹⁷

CXCR4-targeted nanomedicine represents a promising strategy to overcome these structural and molecular barriers by enabling selective delivery to activated HSCs and fibrotic microdomains.¹¹⁸ Multifunctional nanocarriers incorporating CXCR4 antagonists such as AMD3100, peptide inhibitors (eg., LFC131), or CXCR4-binding polymers can simultaneously block CXCL12-mediated chemotactic signaling and enhance site-specific drug accumulation.^78,119,120 Stimuli-responsive nanoplatforms, including ROS-responsive, pH-sensitive, or MMP degradable systems, can further improve tissue penetration by locally responding to the fibrotic microenvironment.¹²¹ These platforms may also enable co-delivery of antifibrotic cargos such as siTGF-β, anti-miR-155, or kinase inhibitors, allowing simultaneous suppression of TGF-β/Smad signaling, inflammatory NF-κB activation, and CXCR4-mediated HSCs recruitment.

Beyond fibrosis attenuation, CXCR4-targeted nanocarriers may synergize with immunomodulatory strategies by regulating macrophage polarization (M2→M1 shift), reducing regulatory T-cell infiltration, and enhancing CD8+ T-cell cytotoxicity through modulation of the CXCR4-driven immune microenvironment.^122,123 Integration of real-time monitoring technologies, such as ultrasound-responsive microbubbles or imaging-capable nanoprobes, can enable dynamic tracking of NP biodistribution, CXCR4 expression levels, and therapeutic response. From a translational perspective, these next-generation CXCR4-targeted multifunctional nanocarriers provide a rational platform to overcome hepatic delivery barriers while simultaneously targeting key profibrotic signaling networks, offering a precision nanomedicine approach for the treatment of progressive LF and HCC.¹²⁴

Redundant Fibrogenic Pathways

Despite the promising efficacy of CXCR4 blockade, LF progression can persist due to redundant signaling pathways that independently activate HSCs. These compensatory mechanisms, which bypass CXCR4 inhibition, involve key mediators such as TGF-β and PDGF. TGF-β signaling promotes ECM deposition by stimulating collagen synthesis and fibrogenic gene expression, while PDGF drives HSCs proliferation, survival, and migration.^65,125 Additionally, integrins, CTGF, and oxidative stress-related pathways contribute to fibrogenesis by enhancing HSCs activation and promoting ECM remodeling.^126,127 Even in the context of CXCR4 inhibition, these signaling pathways sustain fibrotic progression, revealing the limitations of targeting a single pathway.

This compensatory crosstalk between multiple fibrogenic signaling networks necessitates the development of multi-targeted approaches that can overcome redundancy and achieve more comprehensive therapeutic effects. Multifunctional nanocarriers present a promising solution by integrating CXCR4 antagonism with additional therapeutic payloads such as TGF-β inhibitors, PDGF receptor blockers, and antioxidants. By incorporating these synergistic components into a single nanocarrier system, it is possible to simultaneously block multiple pathways, such as CXCL12/CXCR4, TGF-β/Smad, and PDGF/PDGFR, thereby providing a more robust therapeutic response.^128,129 Moreover, these nanoplatforms can be designed to be stimulus-responsive, enabling site-specific drug release in the fibrotic liver, which enhances tissue penetration and drug accumulation at the target site.

In parallel, combination immunotherapy leveraging CXCR4-targeted nanocarriers can further enhance efficacy by modulating the immune microenvironment. For instance, co-delivering immune checkpoint inhibitors (eg., anti-PD-1, anti-CTLA-4) with CXCR4 antagonists could potentially reprogram the TAM population, shifting them from an immunosuppressive M2 phenotype to a pro-inflammatory M1 state.^45,113 This approach could not only inhibit fibrogenic signaling but also promote an anti-tumor immune response, offering a dual benefit in advanced LF and HCC.

Additionally, real-time monitoring platforms, such as ultrasound-responsive nanoprobes or biosensor-enabled imaging systems, can be incorporated into these nanocarriers. These technologies would allow for dynamic tracking of drug delivery, tissue penetration, and therapeutic response in real-time. The development of RGZ/PFP@LNP-RGD, a targeted nanodrug delivery system incorporating Rosiglitazone (RGZ) encapsulated in ultrasound-responsive PFP-based LNPs functionalized with RGD peptides, represents a significant advancement in the noninvasive treatment of LF. This system effectively combines PPARγ agonist therapy with ultrasound-mediated drug release, facilitating precise targeting of activated HSCs, the central players in fibrosis progression. In vitro and in vivo findings demonstrate the potential of RGZ/PFP@LNP-RGD to significantly reduce fibrosis marker expression and improve liver function, underscoring its therapeutic efficacy and translational feasibility. By integrating ultrasound-triggered drug release with precise targeting, this approach exemplifies the future direction of multifunctional nanocarriers in treating LF, enhancing treatment specificity, and offering a viable noninvasive alternative to current fibrosis therapies.¹³⁰ These advanced, multi-targeted nanomedicine platforms provide a notable advantage over single-target therapies by targeting the complex and redundant signaling networks implicated in LF and HCC.^44,131

Drug Resistance & Receptor Desensitization

Prolonged CXCR4 antagonism can lead to receptor internalization and desensitization, which, over time, diminishes the therapeutic efficacy of CXCR4-targeted therapies. In response to sustained blockade, HSCs may upregulate compensatory chemokine receptors such as CXCR7, or activate alternative fibrogenic pathways, allowing the cells to bypass CXCR4 inhibition and sustain ECM production. This redundancy in fibrogenic signaling not only perpetuates LF but also fosters drug resistance.^105,132 Moreover, chronic CXCR4 blockades can trigger feedback mechanisms that reactivate profibrotic signaling cascades, including TGF-β, PDGF, and integrin-mediated pathways, further complicating treatment and driving therapeutic failure.^133,134 These adaptive responses underscore the need for multi-targeted strategies to overcome resistance and prevent the escape of fibrogenic signaling.

In this context, multifunctional nanocarriers offer an innovative approach to simultaneously target multiple key pathways involved in LF. For example, the incorporation of both CXCR4 and CXCR7 antagonists within a single nanoparticle platform could block both receptor-mediated pathways, thereby preventing HSCs from evading treatment.^103,135,136 Additionally, co-delivery of other antifibrotic agents such as TGF-β inhibitors, antioxidants, or immune modulators could further disrupt ECM production and HSCs activation, providing a more comprehensive approach to fibrosis treatment. By designing nanocarriers with stimulus-responsive features, such as ROS-sensitive or pH-responsive drug release, it becomes possible to enhance therapeutic precision and maximize drug accumulation within fibrotic tissues. Moreover, combination immunotherapy involving CXCR4 antagonists in conjunction with immune checkpoint inhibitors or macrophage reprogramming agents could synergize with these nanocarriers, reshaping the immune microenvironment and enhancing immune-mediated anti-fibrotic effects.^75,109 Targeting the fibrotic immune niche in addition to the fibrogenic signaling pathways could prevent immune evasion and bolster the long-term success of antifibrotic therapy.

Finally, the integration of real-time monitoring platforms such as ultrasound-responsive nanocarriers or biosensor-enabled imaging technologies would allow for dynamic tracking of drug distribution, fibrosis regression, and therapeutic response. This enables precise adjustments in treatment, ensuring more efficient drug delivery and providing timely feedback on the effectiveness of combination therapies. Together, these innovative strategies incorporating multifunctional nanocarriers, combination immunotherapy, and real-time monitoring represent a promising approach to overcome drug resistance and receptor desensitization, while offering the potential for more durable and effective treatments for LF and HCC.¹³⁷

Liver Sinusoidal Endothelial Cells Capillarization

In LF, LSECs undergo capillarization, a pathological process that leads to the loss of their characteristic fenestrations. This structural alteration disrupts the physiological filtration barrier, significantly impairing the ability of NPs to penetrate the space of Disse, the critical microenvironment where HSCs reside.¹³⁸ As the fenestrations narrow, drug delivery to activated HSCs becomes increasingly inefficient, which not only compromises the efficacy of targeted therapies but also limits their ability to disrupt the fibrogenic pathways driving disease progression. The capillarization of LSECs, along with the altered ECM and microvascular architecture, exacerbates fibrosis by restricting therapeutic access, thereby perpetuating disease progression through impaired molecular and cellular exchange.

To overcome this biological barrier, innovative approaches are needed. One potential solution is the development of multifunctional nanocarriers that can penetrate the altered fenestrations and improve drug delivery to the fibrotic liver. NPs designed with fenestration-penetrating capabilities, such as size-tuned or biodegradable NPs, could navigate through the restricted openings in the sinusoids and target activated HSCs more efficiently. The development of a SNA NPs carrying miR-325-3p offers a novel and promising alternative to MSCs therapy for LF. This SNA NPs specifically targets fibrotic LSECs through scavenger receptor A (Scara), enabling precise delivery to the key cells involved in fibrogenesis. In preclinical studies, SNA NPs treatment successfully restored LSECs fenestrations, reversed capillarization, and significantly reduced fibrosis, without inducing any adverse effects. These findings underscore the potential of SNA-based nucleic acid therapies as a targeted approach to modulate the fibrotic microenvironment and provide a more precise, non-invasive alternative to conventional therapies.¹³⁹ The use of targeted nucleic acid delivery to LSECs not only highlights a new direction for fibrosis treatment but also opens the door to innovative therapeutic strategies for addressing liver disease at the cellular level, offering significant hope for improved patient outcomes in the future. Additionally, stimuli-responsive nanocarriers, engineered to release their therapeutic payloads in response to fibrotic microenvironmental cues (eg., ROS levels, acidic pH, or matrix stiffness), could further enhance drug accumulation within fibrotic regions and improve treatment efficacy.

Moreover, combination immunotherapy could synergize with these nanocarriers to enhance therapeutic outcomes. By integrating CXCR4 antagonists or immune checkpoint inhibitors into the nanocarrier design, it would be possible to target both the fibrogenic signaling in HSCs and the immunosuppressive TME. Such approaches would not only address fibrosis at the cellular level but also enhance the immune system’s ability to combat fibrosis and potential tumor formation. Furthermore, macrophage reprogramming or T cell activation through the nanocarrier system could break the fibrotic immunosuppressive loop, creating a more favorable microenvironment for therapeutic intervention. Finally, the integration of real-time monitoring platforms, such as ultrasound-responsive nanocarriers or biosensor-enabled imaging, would provide valuable feedback on the distribution, retention, and therapeutic response of the nanocarriers. These monitoring platforms could be used to track the biodistribution of nanocarriers, assess liver perfusion, and measure the fibrotic regression in real-time, enabling precise adjustments in treatment. This would enhance drug delivery efficiency and allow for the dynamic monitoring of disease progression and treatment efficacy.

By combining fenestration-penetrating multifunctional nanocarriers, combination immunotherapies, and real-time monitoring platforms, may lead to the development of more effective, targeted treatments for LF. These strategies have the potential to overcome current delivery limitations and provide translational feasibility for the clinical management of fibrotic liver diseases.^140,141

Future Perspectives

Enhanced Nanocarrier Design for Multi-Barrier Penetration

Future studies should focus on developing smart NPs that can overcome key biological barriers, such as KC clearance and ECM trapping, while enhancing HSCs specific uptake. The challenge in LF treatment lies in the inefficient delivery of therapeutic agents to activated HSCs, which are the primary drivers of ECM deposition. To address this, future research should refine nanocomplex design to enhance stability, prolong systemic circulation, and enable controlled drug release specifically within the fibrotic niche. Incorporating stimuli-responsive features, such as pH- or enzyme-triggered release mechanisms, could improve the selective activation of NPs at fibrotic or tumor sites. Additionally, dual-ligand targeting strategies, such as the combination of CD44 and αvβ3 integrin, could improve HSCs targeting, while further integrating stimuli-responsive elements, such as pH/ROS/enzyme-cleavable linkers, would enable precise drug release in the TME. Expanding the therapeutic potential of nanocomplexes by co-delivering siRNAs targeting pro-fibrotic factors (eg., TGF-β) and oncogenic pathways (eg., CXCR4/MMP-9) could better address the progression from fibrosis to HCC. Additionally, immune microengineering strategies, such as combining KC depletion with TAMs reprogramming (eg., anti-PD-1), may enhance both anti-fibrotic and anti-tumor effects. Optimizing the nano-biointerface with stealth coatings (eg., polydopamine instead of PEG) can further reduce systemic clearance and increase liver accumulation. Moreover, dual-targeting strategies that address both activated HSCs and tumor-associated stromal cells may broaden the scope of therapeutic applications for HCC. The integration of imaging agents for real-time monitoring could facilitate adaptive dosing and improve treatment safety. AI-driven dosing algorithms, informed by real-time fibrosis biomarkers (eg., PIIINP), could optimize therapeutic windows, while patient-derived liver-on-chip models may enable personalized testing of NPs before clinical implementation. These advancements could work synergistically to overcome biological barriers, enhance drug efficacy, and pave the way for adaptive, patient-specific therapies targeting both liver fibrosis and HCC.

Combination with Immunotherapy

The future of HCC and LF treatment lies in the refinement of multi-targeted therapeutic approaches that combine CXCR4 antagonists with immunotherapy. The CXCL12/CXCR4 signaling axis plays a central role in both fibrosis progression and immune evasion within the TME, making it an attractive target for combination therapy. Disrupting this axis has the potential to simultaneously address the immunosuppressive effects of fibrosis and tumor immune evasion, thereby enhancing the effectiveness of immunotherapy in HCC and LF.^45,142

In the context of HBV-related HCC, next-generation therapies could focus on dual blockade of CXCL12/CXCR4 signaling axis, utilizing agents such as motixafortide in combination with N-CCR4-Fc fusion proteins, alongside PD-1 inhibitors. This approach could counteract Treg-mediated immunosuppression and promote a more robust anti-tumor immune response, while maintaining peripheral immune homeostasis.^99,143 In LF, CXCR4 antagonism can disrupt the activation of HSCs, reduce ECM deposition, and prevent the progression to HCC, providing a dual benefit in managing both fibrosis and cancer.⁴⁴ Emerging nanodelivery systems, such as CXCR4-targeted NPs co-loaded with sorafenib and MEK inhibitors, could further enhance precision and minimize off-target effects, addressing the challenge of MAPK pathway reactivation. These systems could improve drug delivery to specific sites in the liver, optimizing therapeutic efficacy while reducing systemic toxicity. The integration of theranostic platforms that enable real-time monitoring of CXCR4 activity offers additional promise by guiding adaptive dosing strategies and facilitating early intervention in high-risk patients.⁶⁵ Such platforms, incorporating CXCR7-agonist-coupled imaging probes, could enable the detection of CXCR4/CXCR7 imbalance during pre-cirrhotic stages, allowing for timely, ligand-specific therapies that favor liver regeneration over fibrosis. Additionally, the combination of CXCR4 blockade with other novel therapeutic modalities, such as bispecific antibodies, oncolytic viruses, and engineered T cells, could more effectively disrupt immune evasion networks, further enhancing the immune response against both HCC and fibrotic tissues.

Multifunctional nanocarriers designed to deliver CXCR4 antagonists alongside immunomodulators would allow for controlled and targeted delivery within fibrotic and TME, minimizing systemic exposure while improving localized therapeutic efficacy.^144,145 Advances in nanodelivery systems could also incorporate epigenetic modulators targeting TCF1/PD-1 and Treg chromatin remodeling, alongside antifibrotic agents such as PAI-1 siRNA. This combination could simultaneously degrade the ECM and reprogram the fibrotic microenvironment, creating a more conducive environment for immune cell infiltration and tumor control. However, challenges remain, including the need for personalized treatment regimens tailored to etiology-specific fibrosis, such as NASH or viral-related fibrosis, and the long-term safety concerns associated with chronic CXCR4 modulation.

These combined strategies have the potential to shift the treatment paradigm from managing advanced liver diseases to preventing HCC in high-risk patients with cirrhosis. To fully realize the potential of these combination therapies, collaborative clinical trials evaluating CXCR4 inhibitors in combination with immune checkpoint blockers are urgently needed. These studies will be critical in validating the synergies between CXCR4 blockade and immunotherapy, potentially leading to more effective, personalized, and adaptive therapeutic options for HCC and liver fibrosis.

ROS-Responsive Drug Release Systems

The development of ROS-responsive drug release systems, particularly dextran-based NPs, presents a promising advancement in precision therapy for LF and HCC. These NPs are designed to exploit the elevated levels of ROS commonly found in fibrotic liver tissue, enabling the targeted release of antifibrotic agents such as sorafenib directly at the affected sites while minimizing systemic toxicity. By incorporating ROS-degradable dextran carriers, the system can selectively release the drug in response to oxidative stress, reducing off-target effects and improving therapeutic efficacy. This approach is particularly advantageous in the context of HCC, where MAPK activation plays a critical role in tumor progression, as the targeted delivery of sorafenib can prevent the unintended activation of this pathway.¹⁴⁶

Future perspectives in nanotechnology for LF and HCC treatment could focus on the development of multi-stimuli-responsive systems that react not only to ROS but also to enzymatic or pH changes characteristic of the fibrotic microenvironment. Such systems could further optimize drug release in response to specific pathological triggers, ensuring that therapeutic agents are activated at precisely the right time and place.

A key strategy would involve the combination of ROS-responsive NPs with CXCR4-targeted therapies. CXCR4, a receptor overexpressed in both HCC and fibrotic liver tissue, is implicated in tumor progression and fibrosis. By incorporating CXCR4 antagonists into these systems, the NPs could simultaneously disrupt fibrogenic signaling and inhibit pro-tumorigenic pathways, offering a dual therapeutic benefit. Studies have shown that CXCR4 antagonism can reduce HCC metastasis, promote immune cell infiltration, and inhibit tumor growth, making it a promising target for combination therapies.

Additionally, integrating immunomodulatory agents, such as PD-1 inhibitors, into ROS-responsive NPs would allow for a comprehensive approach to both LF and immune evasion in HCC. The CXCL12/CXCR4 signaling axis has been shown to play a pivotal role in immune evasion, particularly through the recruitment of immunosuppressive cells like regulatory T cells (Tregs) and TAMs. Combining CXCR4 blockade with PD-1 inhibition could enhance T-cell-mediated anti-tumor immunity while also addressing the fibrotic microenvironment. This strategy has the potential to improve the therapeutic outcomes of both antifibrotic and anti-cancer treatments in HCC, by reducing fibrosis and enhancing immune system activation simultaneously.

The integration of theranostic capabilities into ROS-responsive dextran NPs could further revolutionize treatment monitoring. By incorporating imaging probes such as ROS-sensitive fluorescent dyes, these systems could enable real-time tracking of treatment responses. Such monitoring would allow for the adjustment of dosing regimens based on the specific dynamics of the fibrotic or TME, improving the accuracy and efficiency of therapy. Moreover, the ability to monitor ROS levels in vivo could help identify patients who would benefit most from ROS-responsive treatments, enhancing the precision of the therapeutic approach.

While challenges remain, such as issues related to the biodegradability of the carriers and the scalability of production, advancements in biomaterials and nanotechnology are likely to overcome these hurdles. Future developments in this field will likely lead to the clinical translation of these ROS-responsive systems within the next decade.

In conclusion, the combination of ROS-responsive drug release systems with CXCR4 targeting represents a highly promising approach for the treatment of LF and HCC. By leveraging precise, site-specific drug delivery and addressing both the fibrotic and immune components of the liver microenvironment, these systems have the potential to significantly improve clinical outcomes and prevent disease progression in high-risk patients.

Early Diagnosis via Theranostic Nanoplatforms

The development of CXCR4-targeted micelles, such as CTCE9908-modified stearic acid-grafted chitosan micelles (SCLMs), represents a significant advancement in precision medicine for the treatment of LF. These nanocarriers are engineered to both diagnose and treat fibrosis by integrating ONOO⁻-responsive fluorescent probes with antifibrotic agents like silibinin. The micelles selectively target CXCR4-overexpressing HSCs, allowing for real-time imaging of fibrotic lesions while delivering therapeutic agents directly to the affected areas. This dual functionality enables clinicians to monitor treatment efficacy dynamically, adjusting regimens based on biomarker-driven feedback.¹⁴⁷

The potential for improving CXCR4-targeted micelles lies in the integration of multiplexed sensing capabilities, allowing for the detection of a wider range of fibrosis and tumor-associated biomarkers. This would enable more accurate staging and earlier diagnosis of liver diseases, improving therapeutic outcomes. By simultaneously targeting multiple biomarkers, these advanced micelles could offer a comprehensive approach to diagnosing and treating both LF and its progression to HCC.

One of the most exciting possibilities is the co-loading of CXCR4-targeted micelles with a combination of antifibrotic agents and immune checkpoint inhibitors. This dual approach would address both the fibrotic remodeling and immune evasion mechanisms that are often present in high-risk patients with liver diseases, including those with advanced fibrosis or early-stage HCC. By reprogramming the immune microenvironment, CXCR4 antagonists could enhance the efficacy of immunotherapies, such as PD-1 inhibitors, while simultaneously reducing fibrosis progression and improving liver function.

Additionally, the integration of stimuli-responsive release mechanisms, such as pH-sensitive or enzyme-triggered drug release, would enable site-specific activation, ensuring that the therapeutic agents are only released within the fibrotic or TME. This approach would improve the precision of the treatment while minimizing systemic side effects.

Real-time imaging, coupled with AI, could further personalize dosing schedules and predict therapeutic outcomes based on dynamic biomarker feedback. By incorporating AI-driven algorithms, clinicians could optimize therapeutic windows and adjust treatments based on individual patient profiles, leading to more tailored and effective management of liver diseases.

Next-Gen CXCR4 Antagonists with Improved Safety

The development of next-generation CXCR4 antagonists, such as DBPR807, offers significant promise in the treatment of HCC and LF, with improved safety profiles compared to traditional therapies like sorafenib. DBPR807, a highly selective CXCR4 antagonist, has demonstrated superior efficacy by not only inhibiting tumor growth in HCC but also preventing metastasis, reprogramming the TME, and restoring immune function. This is achieved through the reduction of TAMs and the promotion of cytotoxic T-cell infiltration, ultimately enhancing the immune response against HCC. Its dual anti-angiogenic and immunomodulatory properties further position DBPR807 as a promising candidate in treating LF, where CXCR4 overexpression plays a critical role in HSCs activation and ECM deposition. One key future direction is leveraging DBPR807’s ability to disrupt fibrogenic signaling while simultaneously synergizing with immunotherapy agents, such as anti-PD-1 inhibitors, to combat fibrosis-associated HCC. By targeting the CXCR4/CXCL12 axis, DBPR807 could reprogram the fibrotic TME, increasing the efficacy of immune checkpoint blockade and enhancing T-cell-mediated anti-tumor responses. This combination could address the challenge of immunosuppression in HCC and improve therapeutic outcomes in advanced stages of the disease.⁷¹

Furthermore, the integration of DBPR807 with advanced drug delivery systems, such as HSCs-targeted nanocomplexes like PAMD-CLD-siPAI-1, could optimize drug distribution while overcoming biological barriers such as Kupffer cell clearance and ECM entrapment. These nanocomplexes could selectively target activated HSCs, delivering CXCR4 antagonists directly to fibrotic tissues, thereby enhancing antifibrotic effects and reducing systemic toxicity. By improving the targeted delivery of therapeutic agents, these systems would improve the precision of treatments for both HCC and LF.

Another promising approach is combining DBPR807 with agents targeting complementary pathways involved in fibrosis and tumor angiogenesis, such as TGF-β or VEGF inhibitors. The CXCL12/CXCR4 signaling axis is known to regulate tumor vasculature, and by blocking CXCL12-driven vascularization, DBPR807 could work synergistically with these agents to provide a broader approach to tumor control and fibrosis resolution. This combination could not only inhibit tumor growth and metastasis but also prevent the progression of LF to HCC, thus, making it an ideal candidate for HCC and fibrosis therapy.

Real-time imaging biomarkers to track CXCR4 expression and immune cell dynamics represent a critical tool for optimizing treatment regimens. By using these biomarkers, adaptive dosing strategies could be employed, allowing for timely intervention and personalized treatment based on CXCR4 expression levels and immune cell infiltration. This approach could improve the precision of therapeutic interventions, ensuring optimal dosing while minimizing the risk of off-target effects and immune dysregulation.

To expand the applicability of CXCR4-targeted therapies, future research should include a broader range of fibrosis models, including metabolic and non-viral etiologies. By incorporating these models, the therapeutic potential of DBPR807 could be explored across various liver disease pathologies, offering a more comprehensive approach to treating diverse forms of LF and HCC. This would enhance the clinical relevance of CXCR4 antagonism and its integration with other treatment modalities in a variety of patient populations.

Ultimately, a multidisciplinary approach integrating nanomedicine, immunotherapy, and precision diagnostics could position next-generation CXCR4 antagonists, like DBPR807, as a cornerstone in the treatment and prevention of fibrosis-driven hepatocarcinogenesis. By improving the safety and efficacy of these therapies, they hold the potential to revolutionize the management of HCC and liver fibrosis, providing patients with more effective, personalized, and adaptive treatment options.

Gene Therapy Integration

The integration of gene therapy, particularly CXCR4-targeted gene editing, presents an exciting avenue for treating LF and preventing HCC. CXCR4 has emerged as a critical mediator in both fibrogenesis and tumor progression, making it a prime target for gene-based interventions. By utilizing advanced gene-editing tools like siRNA and CRISPR-Cas9 systems to disrupt the CXCR4/CXCL12 signaling axis or silence profibrotic genes, such as PAI-1, these therapies have the potential to halt or reverse LF while preventing the onset of HCC.^41,148

Future research should prioritize optimizing gene-editing efficiency in vivo to achieve sustained silencing of target genes, especially within the liver. Using advanced delivery platforms, such as LNPs or viral vectors, engineered with CXCR4-binding peptides, could significantly enhance tissue specificity, ensuring that gene theraputics are delivered precisely to aHSCs. This would reduce off-target effects, which is crucial for minimizing systemic toxicity and enhancing the overall therapeutic efficacy. Additionally, incorporating biodegradable, immune-stealth materials into delivery systems could mitigate inflammatory responses and prolong the circulation time of therapeutic payloads, further improving therapeutic outcomes.

A promising strategy would be the combination of CXCR4-targeted gene therapies with immune checkpoint inhibitors, such as anti-PD-1 antibodies. Preclinical studies have shown that disrupting CXCR4 signaling in HCC not only reduces fibrosis but also promotes an immunostimulatory microenvironment, enhancing the efficacy of immunotherapy. CXCR4 antagonism has been shown to reprogram the TME, reduce TAMs, and promote the infiltration of cytotoxic T cells, all of which can increase the sensitivity of tumors to immune checkpoint blockade. Thus, combining CXCR4-targeted gene therapies with PD-1 inhibitors could offer a dual approach to reduce LF and enhance anti-tumor immunity in early-stage HCC.

Additionally, as gene delivery technologies advance, the integration of multiplexed gene editing holds great potential. Simultaneously targeting multiple profibrotic factors such as PAI-1 and TGF-β could offer a more comprehensive approach to addressing the complex pathophysiology of LF while also preventing the progression to HCC. The use of CRISPR-Cas9 to directly edit these pathways within aHSCs could provide a more curative solution to advanced fibrosis, potentially halting the transition to cancer. Furthermore, the ability to personalize therapies by tailoring siRNA sequences to target individual genetic variants associated with fibrotic pathways would further enhance treatment precision and efficacy.

The integration of real-time imaging markers into gene delivery platforms would also be an important future advancement. This would allow for dynamic monitoring of gene silencing or editing efficiency, enabling adaptive treatment adjustments. Monitoring CXCR4 activity in real-time would allow clinicians to assess the effectiveness of gene therapies and make necessary modifications during treatment, improving outcomes and minimizing the need for invasive procedures.

In conclusion, the future of CXCR4-targeted gene therapies for LF and HCC lies in overcoming the biological barriers to efficient delivery, improving gene-editing precision, and combining these therapies with immunotherapy to tackle both the fibrotic and oncogenic components of liver disease. With ongoing advancements in nanocarrier technology, personalized medicine, and multiplexed gene editing, these strategies could offer transformative solutions for patients with LF and HCC, shifting the focus from merely managing advanced disease to preventing its progression.

Personalized Approaches Based on Etiology

The future of CXCR4-targeted therapies in liver disease treatment is intrinsically linked to the principles of precision medicine, where therapeutic strategies are tailored to the underlying etiology of LF and HCC. Personalizing CXCR4-targeted approaches based on the disease’s etiology not only enhances treatment efficacy but also minimizes adverse effects, offering a more precise and effective intervention for patients.

In the case of HBV-related fibrosis and HCC, CXCR4 antagonists, such as motixafortide, show considerable promise when combined with direct-acting antivirals (DAAs) or immune modulators like anti-PD-1 inhibitors. The co-administration of CXCR4 antagonists and DAAs can address both viral replication and fibrogenic signaling, reducing viral load while simultaneously inhibiting the progression of fibrosis. This approach also enhances the restoration of anti-tumor immunity by disrupting the CXCL12/CXCR4 axis, which plays a pivotal role in immune evasion within the TME. Furthermore, preclinical studies have indicated that dual-targeting of CXCR4 and CCR4, through agents like N-CCR4-Fc fusion proteins, could optimize outcomes by overcoming redundant immunosuppressive pathways, offering a promising strategy in HBV-related HCC treatment.⁴⁵

For NASH-driven fibrosis, where the underlying pathophysiology is largely metabolic, CXCR4 inhibition could work synergistically with metabolic regulators, such as FXR agonists and GLP-1R analogs. These agents reduce inflammation and inhibit HSCs activation, a key driver of fibrosis in NASH. By incorporating CXCR4 blockade into this therapeutic regimen, the modulation of fibrogenic pathways can be further enhanced, preventing the progression of NASH to HCC. Additionally, emerging research on CXCR4-targeted NPs offers exciting possibilities for enhancing liver-specific drug delivery. For example, NPs loaded with siRNA targeting the HBV X protein or lipid-lowering drugs could more efficiently deliver therapeutic agents directly to the liver, further optimizing the treatment of HBV-related LF and HCC.¹⁸

Biomarker-guided therapies are another area where CXCR4 modulation could be personalized. High CXCL12 expression or CCR4+ Treg infiltration in the liver could serve as biomarkers for identifying patients who are more likely to benefit from CXCR4-targeted therapies. This targeted approach ensures that treatment is directed at those who are most likely to experience therapeutic benefit, increasing the precision and effectiveness of the therapy. Moreover, patient stratification based on CXCR4 expression and Treg infiltration could also help in predicting response to immunotherapy, further tailoring treatment for HCC patients.

Finally, the integration of advanced nanotechnology for personalized treatment is a key area of innovation. NPs engineered to target both CXCR4 and other molecular pathways specific to liver diseases, such as metabolic dysfunction in NASH or viral replication in HBV-related fibrosis, could offer multi-faceted therapeutic solutions. By incorporating CXCR4-targeted NPs into combination therapies, such as those targeting the immune checkpoint pathways, or by co-delivering epigenetic modulators and antifibrotic agents, these systems can not only enhance drug delivery but also reprogram the liver microenvironment to improve immune cell infiltration and efficacy of the treatment.

In conclusion, personalized approaches based on the etiology of LF and HCC, combined with CXCR4-targeted therapies, represent the future of liver disease treatment. The integration of CXCR4 inhibition with other disease-specific therapies whether antiviral agents for HBV, metabolic regulators for NASH, or immune checkpoint inhibitors for HCC could transform how liver diseases are treated, offering more tailored, effective, and safer therapeutic options. Through the use of biomarker-guided strategies and innovative drug delivery systems, these personalized therapies could significantly improve outcomes and pave the way for more individualized treatments for patients with LF and HCC.

Conclusion

The future of LF and HCC treatment lies in the continued development of CXCR4-targeted DDS, which offer the ability to precisely modulate both fibrogenic and tumorigenic pathways. By integrating multifunctional nanocarriers capable of overcoming biological barriers such as ECM entrapment and immune cell clearance, alongside real-time monitoring platforms, these systems hold great promise in enhancing both drug delivery efficiency and treatment safety. The use of combination therapies that incorporate CXCR4 antagonists with immune modulators can effectively target both LF and tumor progression, overcoming redundancy in fibrogenic signaling pathways and minimizing immune evasion. Moreover, the incorporation of biomarker-guided, personalized medicine will refine therapeutic regimens, ensuring treatments are tailored to specific disease etiologies, such as HBV or NASH-induced fibrosis. For CXCR4-targeted DDS to reach their full potential, future research must focus on improving their stability, circulation time, and targeting precision, while addressing challenges like long term safety and scalable production. Ultimately, the clinical translation of these technologies, supported by adaptive dosing strategies and rigorous preclinical validation, could revolutionize treatment strategies for both LF and HCC. This shift from reactive interventions to preventive therapies offers the potential to address fibrosis progression and malignant transformation at earlier stages of disease, leading to better patient outcomes. While preclinical results are promising and clinical trials are underway, further optimization of these delivery systems and their clinical validation are essential for achieving translational success in fibrotic liver diseases and HCC.

Key Takeaways and Implications for Nanomedicine

CXCR4-Targeted DDS for Precision Treatment

The development of CXCR4-targeted DDS offers a precision-driven approach for modulating both fibrogenic and tumorigenic pathways in LF and HCC, providing highly targeted therapeutic interventions.

Overcoming Biological Barriers

By incorporating multifunctional nanocarriers that can overcome key biological barriers such as ECM entrapment and immune cell clearance, CXCR4-targeted DDS hold promise for more efficient and targeted drug delivery to liver tissues.

Combination Therapy Synergies

The integration of CXCR4 antagonists with immune modulators in combination therapies effectively addresses both fibrosis and tumor progression, offering a novel strategy to overcome redundant signaling pathways and enhance treatment efficacy.

Personalized Medicine Integration

Biomarker-guided, personalized medicine is critical for tailoring therapeutic regimens to specific disease etiologies, such as HBV- or NASH-induced fibrosis, ensuring that treatments are optimized for individual patient needs.

Improving Drug Delivery Systems

Future research should prioritize enhancing the stability, circulation time, and targeting precision of CXCR4-targeted DDS, addressing challenges related to long-term safety and the scalability of production.

Shifting to Preventive Therapies

Moving from reactive treatments to preventive therapies, CXCR4-targeted DDS offer the potential to halt fibrosis progression and prevent malignant transformation at earlier disease stages, improving patient outcomes.

Nanomedicine’s Role in Liver Disease Treatment

The continued development of nanocarriers for targeted delivery systems will likely transform treatment strategies in liver diseases by providing more effective, safer, and personalized options.

Adaptive Dosing Strategies

The combination of adaptive dosing strategies with CXCR4-targeted DDS can optimize therapeutic outcomes, particularly in preventing the progression of LF and HCC at earlier stages.

Clinical Validation and Optimization

While promising preclinical results are emerging, rigorous clinical trials and further optimization of these DDS are essential for translating this technology into successful therapeutic options for patients with LF and HCC.

Broad Implications for Nanomedicine

The success of CXCR4-targeted DDS could pave the way for broader applications of nanomedicine in other therapeutic areas, leveraging precision targeting and combination therapies for complex diverse diseases, setting new standards for personalized medicine.